FriendFinder Networks (FFN) Continues To Successfully Optimize Business

FriendFinder Networks Continues To Successfully Optimize Business Resulting In Adjusted EBITDA Of $8.0 Million For July 2012

SUNNYVALE, Calif., Sept. 13, 2012 /PRNewswire/ — FriendFinder Networks Inc. (NasdaqGM: FFN) (the “Company”), a leading internet and technology company providing services in the rapidly expanding markets of social networking and web-based video sharing, today announced improved operating results.

“As highlighted in our recent second quarter earnings release and conference call, FriendFinder Networks has undertaken an aggressive effort to optimize our business and streamline our cost structure. In doing so, we have redirected our efforts to foster stronger growth in our core network of brands,” said Anthony Previte, Chief Executive Officer of FriendFinder Networks. “The overarching goals are to improve new subscriber conversion rates and to reduce churn and customer acquisition costs. For the month of July 2012, these efforts resulted in significant operational improvements, including strong adjusted EBITDA.”

Non-GAAP Financial Measures

Management believes that certain non-GAAP financial measures of earnings before deducting net interest expense, income taxes, depreciation and amortization, or EBITDA, and Adjusted EBITDA are helpful financial measures as investors, analysts and others frequently use EBITDA and Adjusted EBITDA in the evaluation of other companies in FriendFinder Networks Inc.’s industry.

These non-GAAP financial measures may not provide information that is directly comparable to that provided by other companies in FriendFinder Networks Inc.’s industry, as other companies in FriendFinder Networks Inc.’s industry may calculate such financial measures differently, particularly as it relates to nonrecurring, unusual items. The Company’s non-GAAP financial measures of EBITDA and Adjusted EBITDA are not measurements of financial performance under GAAP and should not be considered as alternatives to cash flow from operating activities or as measures of liquidity or as alternatives to net income or as indications of operating performance or any other measure of performance derived in accordance with GAAP.

Management derived EBITDA and Adjusted EBITDA for the month ended July 31, 2012 using the adjustments shown in the attached reconciliation table.

SAFE HARBOR

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Additional information concerning these and other risk factors is contained in the Company’s most recent filings with the SEC, including its Form 10-K for the year ended December 31, 2011. All subsequent written and oral forward-looking statements concerning the Company are expressly qualified in their entirety by the cautionary statements above and subject to such risk factors discussed in the Company’s recent SEC filings. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based.

ABOUT FRIENDFINDER NETWORKS INC.

FriendFinder Networks Inc. (www.FFN.com) is an internet-based social networking and technology company operating several of the most heavily visited websites in the world, including AdultFriendFinder.com, Amigos.com, AsiaFriendFinder.com, Cams.com, FriendFinder.com, BigChurch.com and SeniorFriendFinder.com. FriendFinder Networks Inc. also produces and distributes original pictorial and video content and engages in brand licensing.

Investor Contact for FriendFinder Networks Inc.
Jeffrey Goldberger / Rob Fink
KCSA Strategic Communications
212.896.1206 or jgoldberger@kcsa.com / rfink@kcsa.com

Media Contact for FriendFinder Networks Inc.
Lindsay Trivento
Director, Corporate Communications
561.912.7010 or ltrivento@ffn.com

Reconciliation of GAAP Net Income to EBITDA and Adjusted EBITDA

Month Ended

July 31, 2012

(Unaudited)

(in thousands)

GAAP net income

$

1,083

Add: Interest expense, net

7,109

Subtract/Add: Income tax (benefit)/expense

–

Add: Amortization of acquired intangible assets and software

1,244

Add: Depreciation and other amortization

255

EBITDA

$

9,691

Subtract/Add: (Gain)/Loss related to VAT liability not charged to customers

(1,809)

Add: Discontinued Operations

116

Adjusted EBITDA

$

7,998

Response Genetics (RGDX) Raises $8.8 Million in Financing

Response Genetics Raises $8.8 Million in Financing
Company to Present at UBS Global Life Sciences in NYC on September 20, 2012

LOS ANGELES, Sept. 13, 2012 /PRNewswire/ — Response Genetics, Inc. (Nasdaq: RGDX) announced today that it has entered into a purchase agreement with GlaxoSmithKline and one of its existing significant stockholders to raise $8.8 million from the private placement of 8,000,000 newly issued shares of its common stock at a purchase price of $1.10 per share.

The signing of the purchase agreement and closing of the financing occurred today, Thursday, September 13, 2012.

“We are pleased to welcome GlaxoSmithKline as a new investor, given our long standing relationship,” said Thomas Bologna, chairman and chief executive officer of Response Genetics, Inc. “The capital raised will help support our continued efforts in building a sustainable business of high value genetic tests for cancer patients as well as a premier pharmaceutical services business. Going forward we will continue to implement additional operational efficiencies, as evidenced by our improved financial performance relative to the fourth and subsequent quarters of last year, and will also increase our focus and efforts on growing top line revenue.”

The securities sold in the private placement have not been registered under the Securities Act of 1933, as amended, or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission (“SEC”) or an applicable exemption from the registration requirements. Response Genetics, Inc. has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issued in the private placement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy Response Genetics, Inc.’s common stock.

Thomas A. Bologna, Response Genetic’s chairman & chief executive officer, will present at the UBS 2012 Global Life Sciences Conference taking place at the Grand Hyatt in New York City on Thursday, September 20, 2012 at 11:00 a.m. ET.

Interested investors can access a live webcast of the presentation by going to the Investor Relations tab on the Response Genetics website: www.responsegenetics.com. A replay of the webcast will be made available on the company’s website for 60 days.

About Response Genetics, Inc.

Response Genetics, Inc. (the “Company”) is a CLIA-certified clinical laboratory focused on the development and sale of molecular diagnostic testing services for cancer. The Company’s technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. The Company’s principal customers include oncologists and pathologists. In addition to diagnostic testing services, the Company generates revenue from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The Company’s headquarters is located in Los Angeles, California. For more information, please visit www.responsegenetics.com.

Forward-Looking Statement Notice

Except for the historical information contained herein, this press release and the statements of representatives of the Company related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995.

Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company’s plans, objectives, projections, expectations and intentions, such as the ability of the Company, to provide clinical testing services to the medical community, to continue to expand its sales force, to continue to build its digital pathology initiative, to attract and retain qualified management, to continue to provide clinical trial support to pharmaceutical clients, to enter into new collaborations with pharmaceutical clients, to enter into areas of companion diagnostics, to continue to execute on its business strategy and operations, to continue to analyze cancer samples and the potential for using the results of this research to develop diagnostic tests for cancer, the usefulness of genetic information to tailor treatment to patients, successfully consummate the transactions contemplated by a purchase agreement or to successfully file a registration statement with the SEC, and other statements identified by words such as “projects,” “may,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans” or similar expressions.

These statements are based upon the current beliefs and expectations of the Company’s management and are subject to significant risks and uncertainties, including those detailed in the Company’s filings with the SEC. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company’s control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

Investor Relations Contact:

Company Contact:

Peter Rahmer

Thomas A. Bologna

Trout Group

Response Genetics, Inc.

646-378-2973

323-276-6060

Neuralstem Cells (CUR) Induce Significant Functional Improvement

Neuralstem Cells Induce Significant Functional Improvement In Permanent Rat Spinal Cord Injury, Cell Study Reports
Paralyzed Rats Regain Use of Lower Limbs

ROCKVILLE, Md., Sept. 13, 2012 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that its neural stem cells were part of a study, “Long-Distance Growth and Connectivity of Neural Stem Cells After Severe Spinal Cord Injury: Cell-Intrinsic Mechanisms Overcome Spinal Inhibition,” published online today in a leading scientific journal CELL (http://www.cell.com/current). In the study, rats with surgically transected spinal cords, which rendered them permanently and completely paraplegic, were transplanted with Neuralstem’s spinal cord stem cells (NSI-566). The study reports that the animals recovered significant locomotor function, regaining movement in all lower extremity joints, and that the transplanted neural stem cells turned into neurons which grew a “remarkable” number of axons that extended for “very long distances” over 17 spinal segments, making connections both above and below the point of severance. These axons reached up to the cervical region (C4) and down to the lumbar region (L1). They also appeared to make reciprocal synaptic connectivity with the host rat spinal cord neurons in the gray matter for several segments below the injury.

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

Further study showed that re-transecting the spinal cord immediately above the graft abolished the functional gain, indicating that the regeneration of host axons into the human stem cell graft was responsible for the functional recovery. The cells that Neuralstem contributed to the study, NSI-566, are the same cells used in the recently completed Phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease). Neuralstem has also submitted an application to the FDA for a trial to treat chronic spinal cord injury with these cells.

“This study demonstrates that our neural stem cells can induce regeneration of injured spinal cord axons into the graft and serve as a bridge to reconnect to gray matter motor neurons for many spinal cord segments below the injury,” said Karl Johe, PhD, Chairman of Neuralstem’s Board of Directors and Chief Scientific Officer. “This is important in spinal cord injury because the nerve connections below the point of injury die, causing paralysis. Our cells built a bridge that received inputs from regenerating rat axons above the injury. They also sent out new human axons which made new synaptic connections with the host motor neurons in the gray matter below the injury. The fact that these cells induce regeneration of axons and partial recovery of motor function makes them relevant for testing for the treatment of human spinal cord injury.”

About the Study

In a study of 12 rats, all 12 underwent complete spinal transections at vertebrae, T3. Six of these were subsequently transplanted with Neuralstem spinal cord stem cells (NSI-566) seven days after the injury. This group was assessed over the next seven weeks and compared to the control group, which had not received transplants. The transplanted rats exhibited significant locomotor recovery, regaining movement in all lower extremity joints. A majority of the grafted cells (57%) turned into neurons. From these, the study reported, a remarkable number of axons emerged, extending both above and below the point of spinal cord lesion. These axons expressed synaptic proteins in the host gray matter, which suggests they made synaptic contact with the host spinal neurons.

About Neuralstem

Neuralstem’s patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain’s capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer’s disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem’s technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended June 30, 2012.

Mindspeed (MSPD) and SpiderCloud Innovate on Scalable Enterprise 3G Small Cells

Mindspeed Technologies, Inc. (NASDAQ: MSPD), the leading supplier of small cell technology, today announced that it has co-developed a customized baseband processor with SpiderCloud Wireless featuring software, self-organizing and scalable system features by SpiderCloud. The new processor solution opens the door for mobile operators to roll out scalable deployments of robust indoor 3G systems for medium to large enterprise customers worldwide.

The SpiderCloud Wireless Enterprise Radio Access Network (E-RAN) system uses SpiderCloud’s highly optimized software stack that includes its own physical layer software (PHY) implementation on Mindspeed’s system-on-chip (SoC). The PHY plays a critical role in solving mobility and interference problems of radio nodes, which are controlled and powered by SpiderCloud’s enterprise premises-based services node.

The self-organizing E-RAN, which can be installed in just days by a mobile operator or its partners, delivers reliable 3G coverage and capacity for 100 to 1000s of people using any existing Ethernet Local Area Network (LAN) for backhaul and enterprise services integration, with full mobility and cell-to-cell handoff and synchronization with the operator’s macro cellular network.

“Small cells have quickly become a recognized part of carrier network plans for both metro area and residential services. Still, despite a good deal of focus, the challenges of the corporate environment have been tougher to meet,” said Peter Jarich, Vice President, Consumer and Infrastructure at Current Analysis. “This co-operation, and the level of development that has gone into it, is further evidence of how complex the enterprise segment truly is. More generally, it is an indication of how the small cell market continues to innovate and the opportunities continue to grow.”

“3G small cells are being deployed in homes, small enterprises and outside in metropolitan areas, but until now, the industry has not been able to deliver a true ‘enterprise-grade’ system,” said Raouf Y. Halim, chief executive officer at Mindspeed. “It took years of developments and innovative thinking by Mindspeed and SpiderCloud Wireless to enable such a system, and we’re proud to take part in unlocking the enterprise opportunity for mobile operators.”

Mindspeed is the leader in small cell technology, with 70% share of the high-speed packet access (HSPA) market according to data from ABI Research. Mindspeed is the only small cell SoC company that has demonstrated support for both HSPA and LTE in its small cell SoCs, and the only one to have shown both frequency-division duplexing (FDD) LTE and time-division LTE (TD-LTE) solutions.

“Mindspeed’s technology leadership and ability to provide custom features has helped us bring to market a unique and scalable 3G small cell platform for enterprise deployments by mobile operators,” added Behrooz Parsay, senior vice president of engineering and operations with SpiderCloud Wireless. “SpiderCloud has invested significant time and resources to commercialize a unique PHY, MAC and upper layers solution. We’ve worked closely with Mindspeed in developing our own PHY as part of this new enterprise small cell network, and the combination of this with Mindspeed’s expertise has resulted in a truly market leading system.”

About Mindspeed Technologies

Mindspeed Technologies (NASDAQ: MSPD) is a leading provider of network infrastructure semiconductor solutions to the communications industry. The company’s low-power system-on-chip (SoC) products are helping to drive video, voice and data applications in worldwide fiber-optic networks and enable advanced processing for 3G and long-term evolution (LTE) mobile networks. The company’s high-performance analog products are used in a variety of optical, enterprise, industrial and video transport systems. Mindspeed’s products are sold to original equipment manufacturers (OEMs) around the globe.

To learn more, please visit www.mindspeed.com. Company news and updates are also posted at www.twitter.com/mindspeed.

About SpiderCloud Wireless, Inc.

SpiderCloud Wireless develops breakthrough, small-cell network platforms that allow mobile operators to deliver unprecedented cellular coverage, capacity and smart applications to enterprises. SpiderCloud is based in San Jose, California and is backed by investors Charles River Ventures, Matrix Partners, Opus Capital and Shasta Ventures. For more information, follow the company on twitter at www.twitter.com/spidercloud_inc or visit www.spidercloud.com.

SpiderCloud Wireless is a registered trademark and SmartCloud a trademark of SpiderCloud Wireless, Inc. ©2012 SpiderCloud Wireless, Inc.

Point.360 (PTSX) Announces Fourth Fiscal Quarter and Fiscal 2012 Results

BURBANK, Calif., Sept. 12, 2012 /PRNewswire/ — Point.360 (NASDAQ: PTSX), a leading provider of integrated media management services, today announced results for the three and twelve month periods ended June 30, 2012, including sales of $35.0 million and income per share of $0.04 for the twelve months ended June 30, 2012. For the quarter ended June 30, 2012, the Company’s sales were $9.0 million generating income of $0.06 per share. The Company also reported $4.5 million of earnings before interest, taxes, depreciation and amortization and non-cash charges (EBITDAN) for the twelve-month period, and EBITDAN of $1.5 million for the three-month period.

Haig S. Bagerdjian, the Company’s Chairman, President and Chief Executive Officer said: “We are pleased with the Company’s return to profitability in the just ended fiscal year. Our cash flow is improving. We have entered into a significant financing arrangement with a major bank. We have also taken major steps to match our capabilities to our customers’ needs by changing facility configurations and lowering costs.”

Mr. Bagerdjian continued: “We are no longer subject to the 2007 noncompetition agreement associated with the sale of our advertising distribution business. Realizing that this market has changed over the last five years, we intend to explore how to take advantage of this opportunity.”

Revenues

Revenue for the quarter ended June 30, 2012 totaled $9.0 million compared to $8.6 million in the same quarter last year. Revenues for the twelve months ended June 30, 2012 were $35.0 million compared to $35.2 million last year. Fluctuations between the periods were due to the timing of service deliveries.

Gross Margin

In the fourth quarter of fiscal 2012, gross margin was $3.6 million (40% of sales), compared to $2.8 million (32% of sales) in the prior year’s fourth quarter. For fiscal 2012, gross margin was $12.9 million or 37% of sales, compared to $10.9 million, or 31% of sales in last year.

Selling, General and Administrative and Other Expenses

For the fourth quarter of fiscal 2012, SG&A expenses were $2.9 million, or 32% of sales, compared to $3.0 million, or 35% of sales, in the fourth quarter of last year. For the twelve months ended June 30, 2012, SG&A expenses were $12.1 million (35% of sales) compared to $13.2 million (37% of sales) last year. SG&A personnel costs have been reduced $0.3 million in the current twelve month period, when compared to the prior year period.

Research and development costs associated with Movie>Q and other projects were $0.4 million in the twelve month period ended June 30, 2011.

During fiscal 2011, the Company decided not to use a portion of the originally-acquired Movie>Q assets, specifically those related to kiosk (vending) machines, in the Movie>Q project. In the twelve month period ended June 30, 2011, the Company recorded a related $684,000 non-cash impairment charge.

Interest expense was $0.2 million and $0.8 million for the three and twelve month periods ended June 30, 2012, and $0.2 million and $0.9 million in the three and twelve month periods ended June 30, 2011. In last year’s twelve-month period, the Company received $0.1 million of interest income from the Internal Revenue Service associated with a $1.5 million tax refund.

Other income in all periods represents sublease income and gain on sale of fixed assets. In the 2012 twelve month period, other income also included a $0.1 million discount on debt repayment. In the prior year twelve-month period, the Company also received $1.0 million from the settlement of a claim. In the prior year twelve-month period, other income was partially offset by a put option expense of $0.1 million.

Operating Income (Loss)

Operating income was $0.7 million in the fourth quarter of fiscal 2012 compared to a loss of $0.3 million in last year’s fourth quarter. For the twelve month period ended June 30, 2012, operating income was $0.8 million compared to a loss of $3.4 million in the prior year’s twelve month period.

Net Income (Loss)

For the fourth quarter of fiscal 2012, the Company reported net income of $0.6 million ($0.06 per share) compared to a net loss of $0.4 million ($0.04 per share) in the same period last year. For the twelve months ended June 30, 2012, the Company reported net income of $0.4 million ($0.04 per share) compared to a net loss of $2.8 million ($0.26 per share) in the prior year period.

Earnings Before Interest, Taxes, Depreciation, Amortization and Non-Cash Charges (EBITDAN)*

The following table reconciles the Company’s EBITDAN to net income (loss) which is the most directly comparable financial measure under Generally Accepted Accounting Principles (“GAAP”):

Computation of EBITDAN (unaudited)*

Three Months Ended

Twelve Months Ended

June 30,

June 30,

2011

2012

2011

2012

Net income (loss)

$(420,000)

$ 615,000

$(2,811,000)

$ 448,000

Interest (net)

247,000

­ ­­197,000

804,000

814,000

Income taxes

—

—

—

—

Depreciation & amortization

833,000

674,000

3,578,000

2,938,000

Other non-cash charges:

Bad debt expense

10,000

8,000

36,000

35,000

Stock based compensation

85,000

43,000

317,000

294,000

Impairment charges

—

—

684,000

—

EBITDAN

$755,000

$1,537,000

$2,608,000

$4,529,000

In the year ended June 30, 2011, the Company recognized $1 million of income from the settlement of a claim. Excluding the claim income, EBITDAN for the twelve month period ended June 30, 2011 was $1,608,000.

Consolidated Statements of Operations (unaudited) *

The table below summarizes results for the three and nine month periods ended June 30, 2011 and 2012:

Three Months Ended

June 30,

Twelve Months Ended

June 30,

2011

2012

2011

2012

Revenues

$ 8,622,000

$ 8,951,000

$ 35,222,000

$ 34,960,000

Cost of services sold

(5,858,000)

5,368,000

(24,343,000)

(22,064,000)

Gross profit

2,764,000

3,583,000

10,879,000

12,896,000

Selling, general and administrative expense

(3,015,000)

(2,864,000)

(13,197,000)

(12,074,000)

Research and development expense

–

–

(352,000)

–

Impairment charge

–

–

(684,000)

–

Operating income (loss)

(251,000)

719,000

(3,354,000)

822,000

Interest expense

(247,000)

(197,000)

(857,000)

(834,000)

Interest income

–

–

53,000

20,000

Other income

78,000

93,000

1,347,000

440,000

Income (loss) before income taxes

(420,000)

615,000

(2,811,000)

448,000

Provision for income taxes

–

–

–

–

Net income (loss)

$ (420,000)

$ 615,000

$ (2,811,000)

$ 448,000

Income (loss) per share:

Basic:

Net income (loss)

$ (0.04)

$ 0.06

$ (0.26)

$ 0.04

Weighted average number of shares

10,529,650

10,513,166

10,646,728

10,513,166

Diluted:

Net income (loss)

$ (0.04)

$ 0.06

$ (0.26)

$ 0.04

Weighted average number of shares

including the dilutive effect of stock

options

10,529,650

10,513,166

10,646,728

10,523,446

Selected Balance Sheet Statistics (unaudited)*

June 30,

2011

June 30,

2012

Working Capital

$ 2,885,000

$ 4,261,000

Property and equipment, net

17,153,000

17,475,000

Total assets

25,395,000

25,971,000

Current portion of long term debt

1,709,000

172,000

Long-term debt, net of current portion

9,711,000

9,236,000

Shareholder’s equity

9,489,000

10,231,000

*The consolidated statements of operations, computation of EBITDAN and presentation of balance sheet statistics do not represent the results of operations or the financial position of the Company in accordance with generally accepted accounting principles (GAAP), and are not to be considered as alternatives to the balance sheet, statement of income, operating income, net income or any other GAAP measurements as an indicator of operating performance or financial position. Not all companies calculate such statistics in the same fashion and, therefore, the statistics may not be comparable to other similarly titled measures of other companies. Management believes that these computations provide additional useful analytical information to investors.

About Point.360

Point.360 (PTSX) is a value add service organization specializing in content creation, manipulation and distribution processes integrating complex technologies to solve problems in the life cycle of Rich Media. With locations in greater Los Angeles, Point.360 performs high and standard definition audio and video post production, creates virtual effects and archives and distributes physical and electronic Rich Media content worldwide, serving studios, independent producers, corporations, non-profit organizations and governmental and creative agencies. Point.360 provides the services necessary to edit, master, reformat and archive clients’ audio and video content, including television programming, feature films and movie trailers. Point.360’s interconnected facilities provide service coverage to all major U.S. media centers. The Company also rents and sells DVDs and video games directly to consumers through its Movie>Q retail stores. See www.Point360.com and www.MovieQ.com.

Forward-looking Statements

Certain statements in Point.360 press releases may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, statements regarding (i) the Company’s projected revenues, earnings, cash flow and EBITDA; (ii) planned focus on internal growth and acquisitions; (iii) reduction of facilities and actions to streamline operations; (iv) actions being taken to reduce costs and improve customer service and (v) new business and new acquisitions. Please also refer to the risk factors described in the Company’s SEC filings, including its annual reports on Form 10-K. Such statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of the Company to be materially different from those expected or anticipated in the forward-looking statements. In addition to the factors described in the Company’s SEC filings, the following factors, among others, could cause actual results to differ materially from those expressed herein: (a) lower than expected net sales, operating income and earnings; (b) less than expected growth; (c) actions of competitors including business combinations, technological breakthroughs, new product offerings and promotional successes; (d) the risk that anticipated new business may not occur or be delayed; (e) the risk of inefficiencies that could arise due to top level management changes and (f) general economic and political conditions that adversely impact the Company’s customers’ willingness or ability to purchase or pay for services from the Company. The Company has no responsibility to update forward-looking statements contained herein to reflect events or circumstances occurring after the date of this release.

Powerwave Technologies (PWAV) Announces New Credit Agreement

Powerwave Technologies, Inc. (Nasdaq:PWAV), a global supplier of end-to-end wireless solutions for wireless communications networks, today announced that it has entered into a new $50 million senior secured credit agreement with P-Wave Holdings, LLC, an affiliate of The Gores Group. Under the credit agreement, the lenders advanced $35 million to the Company, less fees and expenses, and agreed to loan an additional $15 million to the Company upon request from the Company subject to the fulfillment of certain conditions. The new credit agreement also includes an accordion feature that allows the Company to request up to an additional $100 million in term loans from the lenders, which they may advance in their discretion. Proceeds from advances under the new credit agreement will be used to finance working capital and for general corporate purposes.

In connection with this initial loan, the lender received warrants to purchase a total of 2,625,000 shares of the Company’s common stock with an exercise price for the warrants of $0.50 per share, which exercise price is subject to adjustment under the terms of the warrant.

Detailed information regarding the credit agreement and the other transactions contemplated in the credit agreement is included in the Company’s Current Report on Form 8-K dated September 12, 2012, as filed with the Securities and Exchange Commission.

No Solicitation; Unregistered Securities

This press release does not constitute an offer to sell or the solicitation of an offer to buy any security. Neither the warrants nor the shares of common stock underlying such warrants have been registered under the Securities Act of 1933, as amended, or any applicable state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act of 1933, as amended.

Company Background

Powerwave Technologies, Inc., is a global supplier of end-to-end wireless solutions for wireless communications networks. Powerwave designs, manufactures and markets a comprehensive suite of wireless solutions, including antennas, base station products and advanced coverage solutions, utilized in all major wireless network protocols and frequencies, including Next Generation Networks in 4G technology, such as LTE. Corporate headquarters are located at 1801 E. St. Andrew Place, Santa Ana, Calif. 92705. For more information on Powerwave’s advanced wireless coverage and capacity solutions, please call (888)-PWR-WAVE (797-9283) or visit our web site at www.powerwave.com. Powerwave, Powerwave Technologies and the Powerwave logo are registered trademarks of Powerwave Technologies, Inc.

SEFE (SEFE) Completes Initial Prototype of Corona Discharge Electrostatic Motor

SEFE, Inc. (OTCBB/OTCQB: SEFE) (the “Company”), a solutions-driven company developing products and technologies that improve worldwide access to basic resources, including energy, food and water, today announces the completion of a low-power corona discharge motor prototype at its headquarters in Boulder, Colo. This type of electrostatic motor is well suited for medium and high power applications, and represents an additional avenue the R&D team is pursuing for the conversion of atmospheric electricity.

The corona discharge motor employs a dielectric cylinder lined on the inside with thin metallic foil. The motor is surrounded by multiple alternating polarity corona discharge terminals that spray charge onto the dielectric surface when a high voltage is applied. The grounded poles of the motor serve as a current sink. Corona discharge enables the device to handle much higher DC currents than traditional electrostatic motors.

“Our prototype motor serves as a low power proof of concept for this type of electrostatic motor,” stated SEFE Director of Engineering Michael Hurowitz. “We’ll be working to increase the capabilities of these motors to handle much stronger currents as we move forward.”

About SEFE, Inc.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership. SEFE is technology- and solutions-driven, focusing on developing inventions that provide a real-world impact and true profitability. So, success is measured by both a sustainable return on investment, as well as a project’s sustainability from an environmental perspective.

For more information, visit www.SEFElectric.com.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance or achievements to differ materially from anticipated results, performance or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

Dehaier Medical (DHRM) Receives SFDA Approval for DHR-CPAP-C5

BEIJING, Sept. 11, 2012 /PRNewswire-FirstCall/ — Dehaier Medical Systems Ltd. (NASDAQ: DHRM) (“Dehaier”), an emerging leader in the development, assembly, marketing and sale of medical devices and homecare medical products in China, today announced that it has obtained State Food and Drug Administration approval for DHR-CPAP-C5, one of Dehaier’s major proprietary homecare medical devices. The period of validity for the SFDA approval is four years.

(Logo: http://photos.prnewswire.com/prnh/20100422/CNTH001LOGO)

Continuous Positive Airway Pressure (CPAP) has become the first line of treatment for Obstructive Sleep Apnea Syndrome (OSAS) and for some forms of central sleep apnea. CPAP works by creating a pneumatic splint for the upper airway. A flow generator sends pressurized air through air tubing and a mask (usually a nasal mask) and through the nose to the upper airway. The pressurized air prevents the soft tissues of the upper airway from narrowing and collapsing. For proper CPAP treatment, patient can set high enough flow generator pressures to prevent apneas and hypopneas during all sleep stages and in all sleep positions. The SFDA approval indicated that DHR-CPAP-C5 has met the national health and safety standards and it will be launched in China soon.

Dehaier is committed to offering all-in-one solution for diagnosis, treatment and assessment of Obstructive Sleep Apnea Syndrome (OSAS). Currently, DHR-998 (used for diagnosis and treatment evaluation) has been put into the international market upon the receive of the CE Mark in 2011. Dehaier will continue to strengthen the domestic marketing effort for its high margin, proprietary homecare medical products and at the same time, explore new business model and strategic partnership.

“We are excited about the recent SFDA approval for DHR-CPAP-C5 which is another important step towards providing complete solution to fight sleep disorders.” Commented by Mr. Ping Chen, Chairman and Chief Executive Officer of Dehaier Medical, “Developing and expanding the market share of homecare medical equipment has become one of the Dehaier’s critical business strategies because we believe in the tremendous growth potential in Chinese homecare medical market. With great efforts on R&D, product upgrade, diversification of product mix and expansion of patents, Dehaier is well prepared to not only educate the Chinese consumer about the homecare concept, but also serve the upcoming explosive demand for homecare medical equipment. We will seize any chance to become one of leading players in this promising market.”

About Dehaier Medical Systems Ltd.

Dehaier is an emerging leader in the development, assembly, marketing and sale of medical products, including respiratory and oxygen homecare medical products. The company develops and assembles its own branded medical devices and homecare medical products from third-party components. The company also distributes products designed and manufactured by other companies, including medical devices from IMD (Italy), Welch Allyn (USA), HEYER (Germany), Timesco (UK), eVent Medical (US) and JMS (Japan). Dehaier’s technology is based on six patents, nine software copyrights and proprietary technology. More information may be found at http://www.dehaier.com.cn

Forward-looking Statements

This news release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, government approvals or performance, and underlying assumptions and other statements that are other than statements of historical facts, including in particular any implications regarding the SFDA approval for DHR-CPAP-C5. These statements are subject to uncertainties and risks including, but not limited to, product and service demand and acceptance, changes in technology, economic conditions, the impact of competition and pricing, government regulation, future developments in payment for and demand for medical equipment and services, implementation of and performance under the joint venture agreement by all parties, and other risks contained in reports filed by the company with the Securities and Exchange Commission. All such forward-looking statements, whether written or oral, and whether made by or on behalf of the company, are expressly qualified by the cautionary statements and any other cautionary statements which may accompany the forward-looking statements. In addition, the company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

Contact Us

Dehaier Medical Systems Limited
Surie Liu
+86 10-5166-0080
lius@dehaier.com.cn

Dehaier Medical Systems Limited
Tina He
+86 10-5166-0080
hexw@dehaier.com.cn

Cell Therapeutics (CTIC) Announces European Launch of Pixuvri for Non-Hodgkin B-Cell Lymphoma

Cell Therapeutics, Inc. (“CTI”) (NASDAQ and MTA: CTIC), a company focused on translating science into novel cancer therapies, today announced the initiation of the commercial launch of Pixuvri® in the European Union (“E.U.”) with entry into Sweden, Denmark and Finland in September, to be followed by Austria and Norway in early October 2012 and Germany, United Kingdom and the Netherlands in November 2012. CTI plans to expand availability to France, Italy and Spain as well as other European countries in 2013. Pixuvri was granted conditional marketing authorization by the European Commission in May 2012 and is the first medicinal product licensed in the E.U. to treat adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin Lymphoma (“NHL”). In the E.U., there are approximately 37,000 new cases of aggressive B-cell NHL every year.[1],[2]

“Patients with late-stage aggressive NHL who are not eligible for, or who have not responded to, second line therapy, have very limited treatment options and a bleak outlook, with average survival of less than a year,” commented Dr. Ruth Pettengell, Consultant Hemato-Oncologist at St George’s Hospital, London and principal investigator of the Phase III EXTEND study. “The evidence for Pixuvri demonstrates improved efficacy over current treatment options, but without the cardiotoxicity of anthracyclines. By addressing this unmet need, Pixuvri is an important new treatment option for physicians treating this group of patients.”

In the EXTEND (Expanding the reach of anthracyclines with piXanTronE in relapsed or refractory aggressive NHL Disease) study for Pixuvri, when compared with other active single-agent treatments, more patients on Pixuvri achieved a complete response or unconfirmed complete response, and also survived for longer before their disease progressed.[3] Prior to the approval of Pixuvri there was no standard of care for treating patients who failed front line and second line therapy for aggressive B cell NHL. The EXTEND trial is the only randomized controlled clinical study in this patient population establishing the standard of care for this patient population.

“We are pleased to be able to offer the first meaningful treatment option for physicians treating those patients with multiply relapsed and refractory aggressive NHL,” stated James A. Bianco, M.D., President and CEO of CTI. “CTI looks forward to making this innovative product available to healthcare providers across the European Union.”

About Pixuvri (pixantrone)

Pixuvri is a novel aza-anthracenedione with unique structural and physio-chemical properties. Unlike related compounds, Pixuvri forms stable DNA adducts and has demonstrated superior anti-lymphoma activity compared to related compounds[4],[5] Pixuvri was structurally designed so that it cannot bind iron and perpetuate oxygen radical production or form a long-lived hydroxyl metabolite – both of which are the putative mechanisms for anthracycline-induced acute and chronic cardiotoxicity.[6] These novel pharmacologic properties allow Pixuvri to be administered to patients with near maximal lifetime exposure to anthracyclines without unacceptable rates of cardiotoxicity.

In May 2012, Pixuvri received conditional marketing authorization in the E.U. as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive NHL. The benefit of pixantrone treatment has not been established in patients when used as fifth line or greater chemotherapy in patients who are refractory to last therapy. Please refer to the Summary of Product Characteristics (“SmPC”) for the full prescribing information, including the safety and efficacy profile of Pixuvri in the approved indication. The SmPC is available at http://ec.europa.eu/health/documents/community-register/html/h764.htm#ProcList.

CTI is currently accruing patients into a Phase 3 trial comparing pixantrone and rituximab with gemcitabine and rituximab in the setting of aggressive B-cell NHL. European sites will be participating in this study later this year.

Pixuvri is available in the E.U. through Named Patient Programs in those countries where it is not available commercially.

Pixuvri does not have marketing approval in the United States.

About Conditional Marketing Authorization

Similar to accelerated approval regulations in the United States, conditional marketing authorizations are granted in the E.U. to medicinal products with a positive benefit/risk assessment that address unmet medical needs and whose availability would result in a significant public health benefit as determined by the assessment conducted by the European Medicines Agency. A conditional marketing authorization is renewable annually. Under the provisions of the conditional marketing authorisation for Pixuvri, CTI will be required to complete a post-marketing study aimed at confirming the clinical benefit previously observed.

The European Medicines Agency’s (the “EMA”) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after one to three prior regimens for aggressive B‑cell NHL and who are not eligible for autologous stem cell transplant. As a condition of approval, CTI has agreed to have available the PIX306 clinical trial results by June 2015.

About Non-Hodgkin’s Lymphoma

NHL is caused by the abnormal proliferation of lymphocytes, cells key to the functioning of the immune system. It usually originates in lymph nodes and spreads through the lymphatic system. NHL can be broadly classified into two main forms-aggressive and indolent NHL. Aggressive NHL is a rapidly growing form of the disease that moves into advanced stages much faster than indolent NHL, which progresses more slowly.

There are many subtypes of NHL, but aggressive B cell NHL is the most common and accounts for about 50% of NHL cases.[2] After initial therapy for aggressive NHL with anthracycline-based combination therapy, one-third of patients typically develop progressive disease.[7] Approximately half of these patients are likely to be eligible for intensive second-line treatment and stem cell transplantation, although 50% are expected not to respond.[7] For those patients who fail to respond or relapse following second-line treatment, treatment options are limited, and usually palliative only.[7] Pixuvri is the first treatment to receive E.U. regulatory approval for treatment of patients with multiply relapsed or refractory aggressive B-cell NHL.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the market price of CTI’s securities. Specifically, the risks and uncertainties that could affect the development of Pixuvri include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with Pixuvri in particular including, without limitation, the potential failure of Pixuvri to prove safe and effective for the treatment of relapsed or refractory NHL and/or other tumors as determined by the U.S. Food and Drug Administration, that CTI may not market and commercialize Pixuvri in the E.U. as planned, that CTI may not launch Pixuvri in the E.U. this year as planned, that CTI may not be able to complete the PIX306 clinical trial of Pixuvri-rituximab compared to gemcitabine-rituximab in patients who have relapsed after 1 to 3 prior regimens for aggressive B cell NHL and who are not eligible for autologous stem cell transplant by June 2015 or at all as required by the EMA or have the results of such trial available by June 2015 or at all, that CTI may not be able complete a post-marketing study aimed at confirming the clinical benefit observed in the PIX301 trial, that the conditional marketing authorization for Pixuvri may not be renewed, that CTI cannot predict or guarantee the pace or geography of enrollment of its clinical trials or the total number of patients enrolled, that CTI’s average net operating burn rate may increase and CTI’s ability to continue to raise capital as needed to fund its operations in general, and, including, without limitation, competitive factors, technological developments, costs of developing, producing, and selling Pixuvri, and the risk factors listed or described from time to time in CTI’s filings with the Securities and Exchange Commission including, without limitation, CTI’s most recent filings on Forms 10-K, 8-K, and 10-Q. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.

References

European Cancer Observatory, Cancer Fact Sheets, 2008
Harris NL, et al. Ann Oncol. 1999;10(12):1419-32
Pettengell R, Coiffier B, Narayanan G et al. Lancet 2012. Published online May 30th 2012. DOI:10:1-16/S1470-2045(12)70212-7
Cavalletti E, Crippa L, Mainardi P et al. Invest New Drugs 2007;25:187-95
Hagemeister FB. Cancer Chemother Pharmacol 2002;49(suppl 1):S13-20
Cavalletti E, Crippa L, Mainardi P et al. Invest New Drugs 2007;25:187-95
Friedberg ASH Education Book 2011;1:498-505

Media Contact:
Dan Eramian
T: +1-206-272-4343
C: +1-206-854-1200
E: deramian@ctiseattle.com
http://www.CellTherapeutics.com/press_room

Investors Contact:
Ed Bell
T: +1-206-282-7100
F: +1-206-272-4434
E: invest@ctiseattle.com
http://www.CellTherapeutics.com/investors

WSB Holdings (WSB) Investigation by Levi & Korsinsky, LLP

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of WSB Holdings, Inc. in Connection with the Sale of the Company to Old Line Bancshares, Inc.

NEW YORK, Sept. 11, 2012 /PRNewswire/ — Levi & Korsinsky is investigating the Board of Directors of WSB Holdings, Inc. (“WSB” or the “Company”) (Nasdaq: WSB) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to Old Line Bancshares, Inc. (“Old Line”) (Nasdaq: OLBK).

(Logo: http://photos.prnewswire.com/prnh/20120409/MM84375LOGO )

Click here to learn more about the investigation: http://zlk.9nl.com/wsb, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, WSB shareholders will receive approximately $6.12 per share in cash and stock. The transaction has a total approximate value of $49 million. The investigation concerns whether the WSB Board of Directors breached their fiduciary duties to WSB stockholders by failing to adequately shop the Company before entering into this transaction and whether Old Line is underpaying for WSB shares, thus unlawfully harming WSB stockholders. In particular, the Company has reported a book value of $6.90 per share, for the most recent quarter.

If you own common stock in WSB and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit : http://zlk.9nl.com/wsb.

Levi & Korsinsky is a national firm with offices in New York and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. For more information, please feel free to contact any of the attorneys listed below. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph Levi, Esq.
Eduard Korsinsky, Esq.
30 Broad Street – 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Hydrocarb Partners with Duma Energy (DUMA) to Explore for World Class Reserves in Africa Concession

Hydrocarb Energy Corporation is pleased to announce the completion of a farm-out agreement to Duma Energy Corporation (OTCBB:DUMA). Houston-based Duma, with current production in the Gulf Coast, acquires a 39% working interest in Owambo blocks 1714A, 1715, 1814A, and 1815A in northern Namibia.

Kent Watts, Hydrocarb’s Chief Executive, stated, “Our vast and underexplored concession shows tremendous potential based on the data available to date. We have reviewed a third party report already estimating over a billion barrels of un-risked resource potential out of a single identified structure. The Duma partnership allows us to move aggressively towards our ultimate goal, to make a major discovery in Namibia. We anticipate building on new technical findings as the exploration process unfolds.”

The concession, over 5 million acres, is roughly the size of Massachusetts. Northern Namibia has all of the key ingredients for becoming a major oil province, including good reservoir and source rocks. Hydrocarb, as 51% owner, retains its role as operator on all blocks. The new partnership includes NAMCOR, the Namibian National Oil Company as a 10% partner, and Duma at 39%. The commercial terms for the Owambo Petroleum Contract are highly favorable with reasonable onshore operating and exploration costs. Namibia, an English speaking democracy, has proven to be one of the most stable countries on the continent.

Despite its extensive resources, Africa remains greatly under-explored. Recent discoveries of large oil and gas reserves by companies such as Kosmos (NYSE:KOS) and Tullow PLC (LON:TLW) suggest oil and gas production in Africa may be on the verge of dramatic growth. Major and independent players such as Chevron (NYSE:CVX) and Hyperdynamics (NYSE:HDY) have secured huge acreage positions and are budgeting billions of dollars for exploration.

Duma Energy Corp.’s Chief Executive, Jeremy Driver, commented, “Our concession is in the Namibian portion of the Owambo Basin which extends into southern Angola and is one of the largest unexplored onshore basins in Africa.” He went on to say, “This partnership with Hydrocarb fits our core strategy to continuously develop profitable production domestically while also participating in high impact opportunities internationally that have world class potential.”

About Hydrocarb Corp. is a privately held energy exploration and production company targeting major under-explored oil and gas projects in emerging, highly prospective regions of the world. With headquarters in Houston, Texas we maintain offices in Abu Dhabi, UAE and Windhoek, Namibia. For further information: www.hydrocarb.com

About Duma Energy Corp.

Duma Energy Corp. (DUMA) is an aggressive growth company actively producing oil and gas in the continental United States, both on and offshore. Duma also has a significant interest in a 5.3-million acre concession in the Republic of Namibia in Southern Africa. Duma Energy will continue increasing revenue, cash flow, and reserves to fund its aggressive growth through acquisition and participation in projects with the potential of providing exponential returns for shareholders. Further information can be found on the Company’s website at www.duma.com

SEFE (SEFE) Begins Construction of Electroplating Laboratory

SEFE, Inc. (OTCBB/OTCQB: SEFE) (the “Company”), a solutions-driven company developing products and technologies that improve worldwide access to basic resources, including energy, food and water, today announces the beginning of construction of an in-house electroplating/polishing facility at its headquarters in Boulder, Colorado. The facility will be used to support iterative testing of various corona discharge air terminal configurations.

The plating laboratory will support the application of protective coatings to air terminals to reduce oxidation and corrosive effects. In addition, the team will use electropolishing techniques to do process development on air terminal corona emitters. The iterative prototyping approach will be used in conjunction with the Faraday cage facility to rapidly build and test different corona emitter configurations.

“Our plating laboratory will be used to support our air terminal development program on an ongoing basis,” stated SEFE Director of Engineering Michael Hurowitz. “After careful analysis our team has determined pursuing this process development in-house will save significant R&D capital.”

About SEFE, Inc.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership. SEFE is technology- and solutions-driven, focusing on developing inventions that provide a real-world impact and true profitability. So, success is measured by both a sustainable return on investment, as well as a project’s sustainability from an environmental perspective.

For more information, visit www.SEFElectric.com.

Forward-Looking Statements

This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding our expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. We are under no obligation to (and expressly disclaim any such obligation to) update or alter our forward-looking statements, whether as a result of new information, future events or otherwise.

RF Industries’ (RFIL) Third Quarter Sales Increase 51% to a Record $7,472,000

RF INDUSTRIES, LTD. (NASDAQ:RFIL) today announced record quarterly sales and consolidated net income for the third quarter ended July 31, 2012. Net sales increased 51% to a quarterly record $7,472,000 compared to $4,948,000 in the same quarter last year. Consolidated net income was a quarterly record $735,000, or $0.10 per diluted share, compared to consolidated net income of $65,000, or $0.01 per diluted share in the same quarter last year. Consolidated net income for the third quarter last year was affected by non-recurring expenses of approximately $562,000 associated with the acquisition of Cables Unlimited and certain stockholder issues and activities.

RFI also announced that its Board declared a regular quarterly cash dividend of $0.05 per common share, payable October 15, 2012 to shareholders of record on September 30, 2012.

Third Quarter Review

“Our focus in the acquisition of Cables Unlimited (CU) in June 2011 was to capitalize on RFI’s strong product distribution to the wireless industry. Working closely with our distributors, Cables Unlimited designed and introduced the new OptiFlex™ power and fiber optic cabling system for high-speed wireless antenna towers. Multiple larger orders for OptiFlex supports our strategy of leveraging RFI’s wireless product line by incorporating fiber optic and power components.

“Total operating profits increased to $1,094,000 compared to breakeven in the same period last year. We anticipate that strong performance from all business segments should lead to record sales in the fourth quarter ending October 31, 2012,” said Howard Hill, RFI’s CEO.

RF Connector and Cable Assembly segment sales increased 18% to a record $3,871,000 compared to $3,274,000 in the same quarter last year. Operating income for this segment was $669,000, compared to an operating loss of $99,000 in the same period last year. The segment’s loss in the third quarter last year was due to the total of $562,000 in non-recurring acquisition related and other expenses, as discussed above.

Cables Unlimited’s third quarter sales were a record $2,728,000, compared to sales of $909,000 for the 46 day period after its acquisition on June 15, 2011 last year. Gross margin was 35% compared to 37% of sales in the same quarter last year, while operating profitability significantly improved to $446,000, or 16% of sales, compared to $97,000, or 11% of sales in the same quarter last year.

“During the third quarter, CU announced receipt of orders totaling $1,400,000 for its newly designed OptiFlex™ Hybrid Custom Fiber Optic & DC Power Cabling solution and shipped a significant portion of these orders during the quarter. We are extremely encouraged by the subsequent receipt of additional similar-sized orders for this new product,” said Hill.

Bioconnect sales increased 12% to a third quarter record $570,000 compared to $510,000 in the same period last year. Gross margin declined to 39% from 41% of sales due to higher raw materials costs. Operating income declined slightly to $116,000 compared to $121,000 in the same quarter last year as Bioconnect increased hiring and invested in the development of new products for the coming year.

RF Wireless sales increased 19% to $304,000 from $255,000 in the same quarter last year. A change in product mix, combined with customer requested rescheduling of RadioMobile product shipments to a public service organization lowered segment gross margin to 26% compared to 39% of sales in the same quarter last year. The operating loss for this segment was $138,000 compared to $118,000 in the same quarter last year.

“RadioMobile’s product shipments associated with its $2,600,000 contract with the Los Angeles County Fire Department have been rescheduled for delivery in the current fourth quarter and remainder of calendar 2012. We anticipate significant improvement in RF Wireless sales and profitability in the next two quarters,” said Hill.

As of July 31, 2012, RFI reported cash and cash equivalents of $5,630,000, working capital of $13,719,000, a current ratio of 6 to 1, no long-term debt and stockholders’ equity of $19,094,000, or $2.77 per outstanding share.

Nine Months Review

For the nine months ended July 31, 2012, sales increased 46% to $19,703,000 compared to $13,479,000 in the same period last year. Gross margin for the first nine months of fiscal 2012 declined to 45% compared to 51% of sales, primarily due to higher sales of lower-margin products at Cables Unlimited. Consolidated net income increased 77% to $1,455,000, or $0.19 per diluted share, compared to $823,000, or $0.12 per diluted share, in the same period last year.

For the nine month period RF Connector and Cable Assembly segment sales increased 2% to $10,391,000 from $10,144,000 in the same period last year, led by a 6% increase in sales at the RF Connector division. Segment gross margin was 52% compared to 54% in the same period last year. Operating income for this segment was $1,155,000 compared to $1,136,000 for the first nine months of fiscal 2011.

Sales at Cables Unlimited were $6,008,000 for the first nine months of fiscal 2012, compared to sales of $909,000 in the 46 day period after CU’s acquisition on June 15, 2011. Gross margin was 34% compared to 37% of sales for the comparable periods. Operating income was $648,000, or 11% of sales for the nine month period, compared to $97,000, or 11% of sales in the same period last year.

Bioconnect sales increased 11% to $2,012,000 for the nine month period, compared to $1,809,000 in the same period last year, helping to raise gross margin to 42% from 39% of sales in the same period last year. Higher gross margin and lower selling and general expenses, as a percent of sales, increased operating income 30% to $556,000 compared to $427,000 for the same period last year.

RF Wireless segment sales increased 109% to $1,293,000, compared to $617,000 in the same period last year. Gross margin for both periods was 42%. Higher sales and reduced selling and general expenses improved operating profits by $366,000, resulting in a nine month operating loss of $143,000 compared to an operating loss of $509,000 for the same period of fiscal 2011.

For fiscal 2012 to date, under the Company’s previously announced stock repurchase program, RFI has repurchased 324,871 common shares in open market or private transactions.

Third Quarter Conference Call

RFI has scheduled a conference call this morning, Monday, September 10, 2012, at 12:00 p.m. EDT to discuss its results for the quarter. The dial in number is 800-901-5213 and the passcode is #19367094. A simultaneous webcast of the call can be accessed from the Investor Info page at www.rfindustries.com. A replay will be available after 2:00 p.m. EDT at this same Internet address. For a telephone replay, dial 888-286-8010, passcode #41930510, after 2:00 p.m. EDT.

About RF Industries

RFI manufactures, designs and distributes Radio Frequency (RF) connectors and cable assemblies, medical cabling products, RF wireless products, and fiber optic cable products. Coaxial connectors, cable assemblies and custom microwave RF connectors are used for Wi-Fi, PCS, radio, test instruments, computer networks, antenna devices, aerospace, OEM and Government agencies. Medical Cabling and Interconnector products are specialized custom electrical cabling products for the medical equipment monitoring market. RF Wireless products include digital data transceivers for industrial monitoring, wide area networks, GPS tracking and mobile wireless network solutions. Fiber optic cable, connector and harness products serve computer, aerospace, computer networking and specialty applications.

Safe Harbor Statements under the Private Securities Litigation Reform Act of 1995.

This press release contains forward-looking statements with respect to future events which are subject to a number of factors that could cause actual results to differ materially. Factors that could cause or contribute to such differences include, but are not limited to: changes in the telecommunications industry; the operations of the Cables Unlimited division which was acquired in June 2011; unexpected difficulties or delays in implementing the new wireless system upgrade to the Los Angeles County Fire Department’s existing remote communications equipment; and the Company’s reliance on certain distributors for a significant portion of anticipated revenues. Further discussion of these and other potential risk factors may be found in the Company’s public filings with the Securities and Exchange Commission (www.sec.gov), including its Form 10-K. All forward-looking statements are based upon information available to the Company on the date they are published and the Company undertakes no obligation to publicly update or revise any forward-looking statements to reflect events or new information after the date of this release.

RF INDUSTRIES, LTD.

PRELIMINARY CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(in thousands, except per share and share amounts) (unaudited)

Three Months Ended

Nine Months Ended

July 31,

July 31,

2012

2011

2012

2011

Net sales

$

7,472

$

4,948

$

19,703

$

13,479

Cost of sales

4,119

2,532

10,825

6,657

Gross profit

3,353

2,416

8,878

6,822

Operating expenses:

Engineering

261

274

835

904

Selling and general

1,998

2,141

5,847

4,768

Total operating expenses

2,259

2,415

6,682

5,672

Operating income

1,094

1

2,196

1,150

Interest income

11

1

35

23

Income before provision for income taxes

1,105

2

2,231

1,173

Provision for income taxes

370

(63

)

776

350

Consolidated net income

735

65

1,455

823

Net income attributable to deconsolidation of VIE

—

1

2

1

Net income attributable to RF Industries & Subsidiary

$

735

$

64

$

1,453

$

822

Basic earnings per share:

Attributable to RF Industries & Subsidiary

$

0.11

$

0.01

$

0.21

$

0.13

Attributable to VIE

0.00

0.00

0.00

0.00

Consolidated basic earnings per share

$

0.11

$

0.01

$

0.21

$

0.13

Diluted earnings per share:

Attributable to RF Industries & Subsidiary

$

0.10

$

0.01

$

0.19

$

0.12

Attributable to VIE

0.00

0.00

0.00

0.00

Consolidated diluted earnings per share

$

0.10

$

0.01

$

0.19

$

0.12

Weighted average shares outstanding

Basic

6,867,073

6,486,577

6,914,450

6,131,944

Diluted

7,625,085

7,463,169

7,657,546

7,085,996

Dividends paid and payable

343,178

2,313,354

1,038,408

2,528,675

RF INDUSTRIES, LTD. AND SUBSIDIARY
PRELIMINARY CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per share and share amounts)

Jul. 31, Oct. 31,
2012 2011
ASSETS (unaudited)

CURRENT ASSETS:
Cash and cash equivalents $ 5,630 $ 1,761
Restricted cash — 67
Certificates of deposit — 4,095
Trade accounts receivable, net 3,140 2,606
Inventories 6,756 6,189
Prepaid income taxes — 572
Other current assets 594 512
Deferred tax assets 611 611

TOTAL CURRENT ASSETS 16,731 16,413

Property and equipment, net 1,206 2,443
Goodwill 3,076 3,076
Amortizable intangible assets, net 1,682 1,866
Non-amortizable intangible assets 410 410
Note receivable from stockholder 67 67
Other assets 32 103

TOTAL ASSETS $ 23,204 $ 24,378

LIABILITIES AND STOCKHOLDERS’ EQUITY

CURRENT LIABILITIES:
Accounts payable $ 1,182 $ 521
Accrued expenses 1,691 1,580
Mortgages payable — 1,394
Income taxes payable 139 —

TOTAL CURRENT LIABILITIES 3,012 3,495

Deferred tax liabilities 1,072 1,072
Other long-term liabilities 26 133

TOTAL LIABILITIES 4,110 4,700

COMMITMENTS AND CONTINGENCIES

STOCKHOLDERS’ EQUITY:

Common stock – authorized 20,000,000 shares of $0.01 par value; 6,889,424 and 7,110,507 shares issued and outstanding
69 71
Additional paid-in capital 11,682 11,382
Retained earnings 7,343 8,011

Total RF Industries Ltd. and Subsidiary 19,094 19,464

Noncontrolling interest — 214

TOTAL EQUITY 19,094 19,678

TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 23,204 $ 24,378

THIRD QUARTER SEGMENT SALES AND OPERATING INCOME
(in thousands) (unaudited)

RF Connector & Cables RF
Cable Assembly Unlimited Bioconnect Wireless Total

Fiscal 2012

Net sales $ 3,871 $ 2,728 $ 570 $ 304 $ 7,472
Operating Income 669 446 116 (138 ) 1,094

Fiscal 2011

Net Sales 3,274 909

(2)
510 255 4,948
Operating Income $ (99 )

(1)
$ 97 $ 121 $ (118 ) $

1

(1) Operating income in Q3 2011 was affected by $562,000 in non-recurring and other one-time expenses.

(2) Reflects partial quarter results from Cables Unlimited, acquired on June 15, 2011.

zeebox (CHYR) Becomes Charter Partner for Chyron ENGAGE Platform

AMSTERDAM, THE NETHERLANDS — (Marketwire) — 09/10/12 — At IBC2012 today, Chyron announced the integration of its ENGAGE second screen and social TV platform with the zeebox companion app and website that makes watching TV better. With seamless access to zeebox from within their existing Chyron graphics systems, broadcasters can cost-effectively leverage the leading second screen app to complement their live programming.

“The second screen applications running on tablets and other devices serve as an exciting new platform for publishing synchronized content that enhances the viewer’s experience,” said Jim Martinolich, vice president of integration technology at Chyron. “zeebox is the leading second screen app and its integration with our ENGAGE platform aids broadcasters in creating and managing second screen content without introducing significant new production costs. We are very excited to be adding zeebox to our list of ENGAGE charter partners.”

“Broadcasters are clamoring to embrace social TV and second-screen engagement, but the combination of fragmented market, myriad of consumer apps, and lack of integration with their existing workflow has — until now — made this a complex and expensive process,” said Anthony Rose, CTO and co-founder of zeebox. “By giving broadcasters the ability to publish directly into the zeebox platform using their existing tools and production workflow, we’re making it as easy for a broadcaster to create a play-along, social TV or interactive experience delivered within zeebox as it is to pop up an on-screen graphic — and that’s a huge game changer.”

ENGAGE gives broadcasters the ability to add viewer interactivity such as votes, polls, and tweet battles into their live news and sports programming, along with rich call-to-action graphics and infographics. By integrating with popular second screen and social data partners including zeebox, the Chyron platform eliminates the need for custom integration while allowing broadcasters to maintain their routine production workflows. zeebox boosts the ability of broadcasters to offer TV programming that grabs the attention of viewers and fuels greater interactivity. The app gives broadcasters a single program-based destination where fans can chat, share, and interact.

Within the Chyron graphics workflow, the zeebox companion app becomes another layer of rich informational graphics, driven by the newsroom rundown or by the live sports graphics team using the same tools they rely on for daily production. The second screen graphics are created in Chyron’s Lyric graphics creation software, share the same look as the station or group’s on-screen graphics, and are fed by the same sports data feeds that feed on-air programming. Users can even decide on-the-fly which graphics go to air and which graphics go to the second screen.

Chyron will demonstrate the use of zeebox and ENGAGE throughout IBC2012 at its stand 7.D11. More information about Chyron products is available at www.chyron.com.

About zeebox
zeebox is the new, social, interactive and immersive way to watch TV. It turns your smartphone, tablet or laptop into an interactive companion that enables consumers to engage with friends around TV shows, to buy what they see on screen, to remote control their TV, and to get more information about whatever program they’re watching including access to exclusive interactive content.

By partnering with zeebox, broadcasters and content owners can augment their TV shows on the second screen, engage interactively with fans, and monetize this new medium in synch with live TV.

zeebox was founded in 2011 by former iPlayer CTO Anthony Rose and EMI executive Ernesto Schmitt. The company is headquartered in Covent Garden, London, and is expanding rapidly into other countries.

zeebox Press enquiries: hello@zeebox.com

About Chyron
Chyron (NASDAQ: CHYR) is a leading provider of Graphics as a Service for on-air and digital video applications including newsrooms, studios, sports broadcasting facilities, and corporate video environments. An Emmy® Award-winning company whose products have defined the world of digital and broadcast graphics, Chyron’s graphics solutions include the Axis World Graphics online content creation software and order management system, on-air graphics systems, clip servers, channel branding, and graphics asset management solutions, all of which may be incorporated into the company’s BlueNet™ end-to-end graphics workflow. More information about Chyron products and services is available on the company websites: www.chyron.com and www.axisgraphics.tv. The company’s investor relations information is at www.chyron.com via the “Investors” link.

All trademarks and registered trademarks mentioned herein are the property of their respective owners.

Blog: http://chyronchat.com
Facebook: http://www.facebook.com/chyronmelville
LinkedIn: http://www.linkedin.com/company/chyron
Twitter: http://twitter.com/chyronmelville
Tumblr: http://chyronmelville.tumblr.com/
User Forum: http://forum.chyron.com/vbb/index.php
YouTube: http://www.youtube.com/user/chyronmelville
Pinterest: http://pinterest.com/chyron/

Visit Chyron at IBC2012, Stand 7.D11

Photo Link: www.wallstcom.com/Chyron/zeebox.zip

Chyron Contact:
Allyson Patanella
Marketing/PR Coordinator
Tel: +1 (631) 845-2102
Email: apatanella@chyron.com

Agency Contact:
Sarah Schraad
Wall Street Communications
Tel: +1 (303) 567-4048
Email: sarah@wallstcom.com

Optical Cable Corp. (OCC) Reports Fiscal Third Quarter 2012 Financial Results

OCC® Achieves Increases in Net Sales, Gross Profit and Net Income

ROANOKE, Va., Sept. 10, 2012 /PRNewswire/ — Optical Cable Corporation (Nasdaq GM: OCC) (“OCC®” or the “Company”) today announced financial results for its fiscal third quarter ended July 31, 2012. The Company achieved significant increases in net sales, gross profit and net income for both the quarter and year-to-date periods, compared to the same periods in fiscal year 2011.

OCC’s increased sales and strong operating leverage resulted in net income attributable to OCC during the third quarter of fiscal 2012 of almost ten times that of the same period in 2011 and net income attributable to OCC for the year-to-date period in 2012 of more than five times that of the same period in 2011.

Third Quarter 2012 Financial Results

OCC’s consolidated net sales increased 17.2% to $22.0 million for the third quarter of fiscal 2012, compared to consolidated net sales of $18.8 million for the same period last year. The increase in net sales during the third quarter was attributable to increased sales of the Company’s fiber optic cable products.

OCC’s gross profit increased 35.0% to $8.8 million in the third quarter of fiscal 2012, compared to $6.5 million in the third quarter of fiscal year 2011. Gross profit margin, or gross profit as a percentage of net sales, increased to 39.9% in the third quarter of fiscal 2012 from 34.7% in the third quarter of fiscal year 2011.

OCC recorded net income attributable to the Company of $1.2 million, or $0.18 per basic and diluted share, for the third quarter of fiscal 2012, compared to $118,000, or $0.02 per basic and diluted share, for the third quarter of fiscal 2011.

Fiscal Year-to-Date 2012 Financial Results

OCC’s consolidated net sales increased 14.4% to $61.4 million for the first nine months of fiscal 2012, compared to net sales of $53.7 million for the same period last year. The increase in net sales was attributable to increased sales of the Company’s fiber optic cable products.

Gross profit increased 26.1% to $23.8 million in the first nine months of fiscal 2012, compared to $18.9 million in the first nine months of fiscal 2011. Gross profit margin increased to 38.8% in the first nine months of fiscal 2012 from 35.2% in the first nine months of fiscal 2011.

OCC recorded net income attributable to the Company of $2.3 million, or $0.36 per basic and diluted share, for the first nine months of fiscal year 2012, compared to $430,000, or $0.07 per basic and diluted share, for the same period in fiscal year 2011.

Management’s Comments

Neil Wilkin, President and Chief Executive Officer of OCC, said “We are pleased with OCC’s strong sales and earnings performance, as sales of our fiber optic cable products continue to drive top-line growth. In our third quarter, OCC again demonstrated that our operating leverage allows us to deliver disproportionate earnings growth rates relative to our net sales growth rates as fixed costs are spread over larger sales volumes. In addition, we continue to maintain a strong balance sheet and return capital to shareholders through a regular quarterly dividend.”

Mr. Wilkin added, “OCC has a solid sales order forward load, and we expect our sales strength will continue in our fourth fiscal quarter, despite economic weakness. We will continue to execute our strategy to grow OCC and to deliver enhanced shareholder value, and we look forward to a strong finish to our fiscal year.”

Conference Call Information

As previously announced, OCC will host a conference call today, Monday, September 10, 2012, at 10:00 a.m. Eastern Time. Individuals wishing to participate in the conference call should call (888) 868-9083 or (973) 935-8512. For interested individuals unable to join the call, a replay will be available through September 17, 2012 by dialing (800) 585-8367 or (404) 537-3406, pass code 25486985. The call will also be broadcast live over the Internet and can be accessed by visiting the investor relations section of the Company’s website at www.occfiber.com.

Company Information

Optical Cable Corporation (“OCC®”) is a leading manufacturer of a broad range of fiber optic and copper data communications cabling and connectivity solutions primarily for the enterprise market, offering an integrated suite of high quality, warranted products which operate as a system solution or seamlessly integrate with other providers’ offerings. OCC’s product offerings include designs for uses ranging from commercial, enterprise network, datacenter, residential and campus installations to customized products for specialty applications and harsh environments, including military, industrial, mining and broadcast applications. OCC products include fiber optic and copper cabling, fiber optic and copper connectors, specialty fiber optic and copper connectors, fiber optic and copper patch cords, pre-terminated fiber optic and copper cable assemblies, racks, cabinets, datacom enclosures, patch panels, face plates, multi-media boxes and other cable and connectivity management accessories, and are designed to meet the most demanding needs of end-users, delivering a high degree of reliability and outstanding performance characteristics.

OCC® is internationally recognized for pioneering the design and production of fiber optic cables for the most demanding military field applications, as well as of fiber optic cables suitable for both indoor and outdoor use, and creating a broad product offering built on the evolution of these fundamental technologies. OCC also is internationally recognized for its role in establishing copper connectivity data communications standards, through its innovative and patented technologies.

Founded in 1983, OCC is headquartered in Roanoke, Virginia with offices, manufacturing and warehouse facilities located in each of Roanoke, Virginia, near Asheville, North Carolina and near Dallas, Texas. OCC primarily manufactures its fiber optic cables at its Roanoke facility which is ISO 9001:2008 registered and MIL-STD-790F certified, its enterprise connectivity products at its Asheville facility which is ISO 9001:2008 registered, and its military and harsh environment connectivity products and systems at its Dallas facility which is ISO 9001:2008 registered and MIL-STD-790F certified.

Optical Cable Corporation, OCC, Superior Modular Products, SMP Data Communications, Applied Optical Systems, and associated logos are trademarks of Optical Cable Corporation.

Further information about OCC® is available on the Internet at www.occfiber.com.

FORWARD-LOOKING INFORMATION

This news release by Optical Cable Corporation and its subsidiaries (collectively, the “Company” or “OCC”) may contain certain forward-looking information within the meaning of the federal securities laws. The forward-looking information may include, among other information, (i) statements concerning our outlook for the future, (ii) statements of belief, anticipation or expectation, (iii) future plans, strategies or anticipated events, and (iv) similar information and statements concerning matters that are not historical facts. Such forward-looking information is subject to known and unknown variables, uncertainties, contingencies and risks that may cause actual events or results to differ materially from our expectations, and such known and unknown variables, uncertainties, contingencies and risks may also adversely affect Optical Cable Corporation and its subsidiaries, the Company’s future results of operations and future financial condition, and/or the future equity value of the Company. A partial list of such variables, uncertainties, contingencies and risks that could cause or contribute to such differences from our expectations or that could otherwise adversely affect Optical Cable Corporation and its subsidiaries is set forth in Optical Cable Corporation’s quarterly and annual reports filed with the Securities and Exchange Commission (“SEC”) under the heading “Forward-Looking Information.” OCC’s quarterly and annual reports are available to the public on the SEC’s website at http://www.sec.gov. In providing forward-looking information, the Company expressly disclaims any obligation to update this information, whether as a result of new information, future events or otherwise except as required by applicable laws and regulations.

(Financial Tables Follow)

OPTICAL CABLE CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(thousands, except per share data)
(unaudited)

Three Months Ended

Nine Months Ended

July 31,

July 31,

2012

2011

2012

2011

Net sales

$ 22,004

$ 18,775

$ 61,389

$ 53,672

Cost of goods sold

13,217

12,266

37,591

34,795

Gross profit

8,787

6,509

23,798

18,877

SG&A expenses

6,898

6,228

20,273

18,288

Royalty income, net

(22)

(247)

(310)

(645)

Amortization of intangible assets

34

108

101

323

Income from operations

1,877

420

3,734

911

Interest expense, net

(144)

(146)

(427)

(474)

Other, net

(1)

(22)

(4)

14

Other expense, net

(145)

(168)

(431)

(460)

Income before income taxes

1,732

252

3,303

451

Income tax expense

554

178

1,065

175

Net income

$ 1,178

$ 74

$ 2,238

$ 276

Net income (loss) attributable to

Noncontrolling interest

5

(44)

(77)

(154)

Net income attributable to OCC

$ 1,173

$ 118

$ 2,315

$ 430

Net income attributable to OCC

per share: Basic and diluted

$ 0.18

$ 0.02

$ 0.36

$ 0.07

Weighted average shares outstanding:

Basic and diluted

6,667

6,391

6,449

6,306

Cash dividends declared per common share

$ 0.015

$ 0.01

$ 0.045

$ 0.03

OPTICAL CABLE CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEET DATA
(thousands)
(unaudited)

July 31,

October 31,

2012

2011

Cash

$ 1,206

$ 1,092

Trade accounts receivable, net

13,359

10,798

Inventories

19,032

16,497

Other current assets

2,737

3,136

Total current assets

36,334

31,523

Non-current assets

12,674

13,422

Total assets

$ 49,008

$ 44,945

Current liabilities

$ 9,137

$ 8,197

Non-current liabilities

10,184

9,025

Total liabilities

19,321

17,222

Total shareholders’ equity attributable to OCC

30,250

28,209

Noncontrolling interest

(563)

(486)

Total shareholders’ equity

29,687

27,723

Total liabilities and shareholders’ equity

$ 49,008

$ 44,945

AT THE COMPANY:

Neil Wilkin

Tracy Smith

Chairman, President & CEO

Senior Vice President & CFO

(540) 265-0690

(540) 265-0690

investorrelations@occfiber.com

investorrelations@occfiber.com

AT JOELE FRANK, WILKINSON BRIMMER KATCHER:

Andrew Siegel

Aaron Palash

(212) 355-4449 ext. 127

(212) 355-4449 ext. 103

occ-jfwbk@joelefrank.com

occ-jfwbk@joelefrank.com

SOURCE Optical Cable Corporation

Neuralstem (CUR) President And CEO To Present At The 2012 Rodman & Renshaw Conference

Live Webcast on Tuesday, September 11 at 2:00 p.m. EDT

ROCKVILLE, Md., Sept. 10, 2012 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that President and CEO Richard Garr will present at the 2012 Rodman & Renshaw Annual Healthcare Conference on Tuesday, September 11 at 2:00 p.m. EDT, at The Waldorf=Astoria, Starlight South. Garr will discuss the company’s opportunities and advancements in neural stem cell therapy and pharmaceuticals. He will be providing an update on ongoing clinical trials, including the recently completed ALS Phase I, and an overview on future trials. To view the live webcast, visit Neuralstem’s Investor Center at www.neuralstem.com , or: http://www.wsw.com/webcast/rrshq22/cur .

(Logo: http://photos.prnewswire.com/prnh/20061221/DCTH007LOGO )

The 2012 Rodman & Renshaw Annual Healthcare Conference is being held at The Waldorf=Astoria in New York City, September 9-11. For more information, see: http://www.rodm.com/conferences?id=176 .

About Neuralstem

Neuralstem’s patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently completed an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic spastic paraplegia and chronic stroke. The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in chronic spinal cord injury.

Neuralstem also has the ability to generate stable human neural stem cell lines suitable for the systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain’s capacity to generate new neurons, possibly reversing the pathologies of some central nervous system conditions. The company is in a Phase Ib safety trial evaluating NSI-189, its first neurogenic small molecule compound, for the treatment of major depressive disorder (MDD). Additional indications could include chronic traumatic encephalopathy (CTE), Alzheimer’s disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter and Facebook.

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem’s technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the annual report on Form 10-K for the year ended December 31, 2011 and the quarterly report on Form 10-Q for the period ended June 30, 2012.

SOURCE Neuralstem, Inc.

KSW, Inc. (KSW) to Be Acquired by Related Companies

LONG ISLAND CITY, NY and NEW YORK, NY — (Marketwire) — 09/10/12 — KSW, Inc. (NASDAQ: KSW) (“KSW”), a provider of heating, ventilating and air conditioning (HVAC) systems and process piping systems for institutional, industrial, commercial, high-rise residential and public works projects, and Related Companies, a fully-integrated, highly diversified real estate firm with experience in every aspect of real estate development, acquisitions, management, finance, marketing and sales, today announced that they have entered into a definitive merger agreement.

Under the terms of the agreement, a subsidiary of Related Companies (“Merger Sub”) will acquire all of the outstanding shares of common stock of KSW for $5.00 per share in cash through a cash tender offer followed by a merger. The transaction is valued in the aggregate at approximately $32.1 million. The cash consideration represents a premium of approximately 23% to KSW’s closing share price on September 7, 2012, the last trading day before KSW publicly announced the merger. The agreement has been unanimously approved by KSW’s Board of Directors.

Floyd Warkol, CEO of KSW, commented, “We are pleased to announce this merger as it delivers significant value to our shareholders. KSW has enjoyed a long and successful relationship with Related Companies while working on their New York City projects. Partnering with Related Companies will only enhance our ability to provide first quality services to our current and future customers.”

Bruce A. Beal, Jr., President of Related Companies, said, “As a vertically- integrated developer working across all asset classes we are consistently looking for opportunities to enhance our developments and increase our efficiency. The acquisition of KSW, a best-in-class HVAC provider with an experienced management team, allows us to utilize their skill set throughout the design process, offers direct purchasing capability from equipment manufacturers, and creates an even more direct link to New York City’s talented workforce. It will also allow us to continue to pioneer new innovations in sustainability, customizing and developing new sustainable features for our robust pipeline of projects.”

Under the terms of the merger agreement, the parties anticipate that Merger Sub will commence a tender offer for all of the outstanding shares of KSW before September 21, 2012. If the first step tender offer is successfully completed, Merger Sub will acquire any of the KSW shares of common stock not tendered in the tender offer through a second step merger transaction in which the remaining KSW shares are converted into a right to receive the same consideration per share as paid in the tender offer. The tender offer transaction, which is subject to customary closing conditions, is expected to close by October 26, 2012.

Completion of the tender offer is subject to, among other things, the satisfaction of the minimum tender condition of at least a majority of KSW’s outstanding shares of common stock on a fully diluted basis, and other customary closing conditions. The transaction is not subject to a financing condition.

About Related Companies

Related Companies is the most prominent privately-owned real estate firm in the United States. Formed 40 years ago, Related is a fully-integrated, highly diversified real estate firm with experience in every aspect of development, acquisitions, management, finance, marketing and sales. Headquartered in New York City, Related has offices and major developments in Boston, Chicago, Los Angeles, San Francisco, South Florida, Abu Dhabi and Shanghai and boasts a team of approximately 2,000 professionals. The Company’s existing portfolio of real estate assets, valued at over $15 billion, is made up of best-in-class mixed-use, residential, retail, office, trade show and affordable properties in premier high-barrier-to-entry markets. For more information about Related Companies please visit www.related.com.

About KSW

KSW, Inc., through its wholly-owned subsidiary, KSW Mechanical Services, Inc., furnishes and installs heating, ventilating and air conditioning (HVAC) systems and process piping systems for institutional, industrial, commercial, high-rise residential and public works projects. KSW Mechanical Services, Inc. also acts as Trade Manager on larger construction projects, such as the Mt. Sinai Center for Science and Medicine.

Important Information about the Tender Offer

This press release is not an offer to purchase or a solicitation of an offer to sell securities of KSW. The planned tender offer by Merger Sub for all of the outstanding shares of common stock of KSW has not yet commenced. Following the commencement of the tender offer, Merger Sub will mail to KSW stockholders an offer to purchase and related materials and KSW will mail to its stockholders a solicitation/recommendation statement with respect to the tender offer. At the time the offer is commenced, Merger Sub will file a tender offer statement with the U.S. Securities and Exchange Commission (the “SEC”) on Schedule TO, and KSW will file a solicitation/recommendation statement with the SEC on Schedule 14D-9 with respect to the tender offer. Investors and KSW stockholders are strongly advised to read these materials in their entirety (including an offer to purchase, a related letter of transmittal and other offer documents) and the solicitation/recommendation statement when they become available, since they will contain important information that should be considered before any decision is made with respect to the tender offer. KSW stockholders may obtain a free copy of these materials when they become available and other documents filed by Merger Sub or KSW with the SEC at the website maintained by the SEC at www.sec.gov. These materials also may be obtained when they become available for free by contacting the information agent for the tender offer.

Advisors

DLA Piper LLP is acting as legal advisor to Related Companies and Merger Sub. KSW engaged Sandler O’Neill as financial advisor and Bracewell & Giuliani LLP as legal advisor for the transaction.

Cautionary Statements

Statements in this press release that are not historical, including statements regarding KSW’s beliefs, expectations, and strategies, constitute “forward looking statements” within the meaning of the federal securities laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Important factors that could cause the differences are discussed in KSW’s reports on Forms 10-Q, 10-K, and 8-K that it periodically files with the Securities and Exchange Commission. These factors include KSW’s sales process and market acceptance of its products and services, KSW’s capital needs, KSW’s dependence on significant customers and suppliers, risks of a new product offering, risks that KSW may incur significant costs related to self-insurance retention levels for employee benefits and workers’ compensation programs, and the competitive healthcare marketplace. KSW does not undertake to update any forward-looking statements in this press release. Copies of KSW’s SEC filings, including its annual report on Form 10-K and quarterly reports on Form 10-Q, may be obtained by contacting KSW’s general counsel at (718) 340-1409 or at the SEC Filings section of its website at www.kswmechanical.com.

Media/Investor Contacts

For KSW, Inc.:

James F. Oliviero
(718) 340-1409

For Related Companies:

Joanna Rose
(212) 801-3902

Cell Therapeutics (CTI) to update Pixuvri® status at Rodman & Renshaw

Cell Therapeutics, Inc. (CTI) to update Pixuvri® launch and pacritinib pivotal trial status at the Annual Rodman & Renshaw Global Investment Conference

SEATTLE, Sept. 7, 2012 /PRNewswire/ — Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) management will present at the Annual Rodman & Renshaw Global Investment Conference on Tuesday, September 11at 10:25 a.m. Eastern/ 4:25 p.m. Central European/ 7:25 a.m. Pacific time in the Starlight North room of the Waldorf-Astoria Hotel.

The presentation with slides will be webcast live and available for replay after the presentation. The webcast can be accessed at www.celltherapeutics.com.

Annual Rodman & Renshaw Global Investment Conference

CTI presentation: Tuesday, September 11, 2012

10:25 a.m. Eastern/ 4:25 p.m. Central European/ 7:25 a.m. Pacific

Starlight North, Waldorf-Astoria Hotel

Media contact:

Investors contact:

Cell Therapeutics, Inc.

Cell Therapeutics, Inc.

Dan Eramian

Ed Bell

T: 206.272.4343

T: 206.272.4345

F: 206.272.4434

E: invest@ctiseattle.com

E: deramian@ctiseattle.com

www.celltherapeutics.com/investors

www.celltherapeutics.com/press_room

Interim Data From Peregrine’s (PPHM) Phase II Lung Cancer Trial Doubles Survival

Interim Data From Peregrine’s Phase II Trial in Second-Line Non-Small Cell Lung Cancer Demonstrate Doubling of Median Overall Survival in Bavitiximab-Containing Arms

TUSTIN, CA — (Marketwire) — 09/07/12 —

Interim Data from Double-Blind, Placebo-Controlled Trial Presented at Late-Breaking Plenary Session at Leading Oncology Symposium

Data Show Statistically Significant Improvement in Overall Survival for Patients Receiving Bavituximab Plus Docetaxel Versus Docetaxel Alone

Clinical Data Strongly Support Advancing Program into Phase III Clinical Development

Company to Host Conference Call on Monday, September 10, at 11:00 AM EDT

Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced that interim results were presented from its 121 patient randomized, double-blind, placebo-controlled Phase IIb trial in patients with refractory non-small cell lung cancer (NSCLC). The blinded study evaluated two dose levels of bavituximab (bavituximab-containing arms) given with docetaxel versus docetaxel plus placebo (control arm). The interim data showed a statistically significant improvement in overall survival (Hazard Ratio 0.524, p-value .0154) and a doubling of median overall survival (OS) in the bavituximab-containing arms compared to the control arm. The following interim data was presented as part of a late-breaking plenary presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology by David Gerber, M.D., Associate Professor of Internal Medicine at the University of Texas Southwestern Medical Center, a principal investigator in the trial.

—————————————————————————-
Treatment Arm
—————————————————————————-
Bavituximab Bavituximab Bavituximab
Placebo (1 mg/kg) (3 mg/kg) (Pooled Data)
plus docetaxel plus docetaxel plus docetaxel plus docetaxel
—————————————————————————-
Number of
patients (per
protocol 38 40 39 79
population)
—————————————————————————-
Median Overall
Surviva lHazard 5.6 months 11.1 months 13.1 months 12.1 months
Ratio (p-value) — .512 (.0286) .539 (.0714) .524 (.0154)
—————————————————————————-
Overall Response 7.9% 15% 17.9% 16.5%
Ratep-value — .3262 .1895 .2069
—————————————————————————-
Progression Free
Survival Hazard 3.0 months 4.2 months 4.5 months 4.2 months
Ratio (p-value) — .571 (.0794) .65 (.1921) .605 (.067)
—————————————————————————-

“This study was a rigorous trial designed to minimize bias and we are encouraged that this trial yielded such positive results in the most important endpoint, overall survival. The positive overall response rates and progression free survival in both bavituximab-containing arms seen earlier in the study has now translated into a statistically significant extension in overall survival for patients, a result rarely achieved in phase II clinical trials.” said Joseph Shan, vice president of clinical and regulatory affairs at Peregrine. “The quality of this data gives us a solid foundation for designing a phase III trial with an increased probability of success. We are planning for an end-of-phase II meeting with the FDA as we plan to initiate this trial by mid-2013.”

The trial enrolled 121 patients (117 evaluable per the study protocol) with second-line non-squamous NSCLC following one prior chemotherapy regimen at over 40 clinical centers. Patients were equally randomized to 1 of the 3 treatment arms, docetaxel (75mg/m2) plus either placebo, 1 mg/kg bavituximab, or 3 mg/kg bavituximab until disease progression. Approximately 50% of the patients were enrolled in the U.S. and 50% were enrolled internationally with equal distribution between all treatment groups.

“Robust data from this Phase II trial clearly demonstrate a significant benefit in overall survival with a good safety profile in patients receiving bavituximab plus docetaxel compared to those receiving docetaxel plus placebo,” said Steven W. King, president and chief executive officer of Peregrine. “We are currently in discussions with several potential pharmaceutical partners who have expressed great interest in our bavituximab oncology program. It is our goal to identify the optimal partner to assist with the design and logistics of a multinational Phase III pivotal trial.”

The interim results from the study showed no significant safety differences between the three treatment arms as determined by the trial’s independent data monitoring committee. Baseline characteristics were well balanced across all three treatment arms of the study, including performance (ECOG) status, age, gender, and race. Tumor responses were determined in accordance with Response Evaluation Criteria In Solid Tumors (RECIST 1.1) based on blinded central radiology review.

“The median overall survival results from the Proof-of Concept study are truly outstanding and great news for patients. Statistically significant overall survival results at this stage of development are rare and have put us in an excellent position for advancing the program. Our attention is now turned to an end of phase II meeting by year end which will help us define the most efficient path forward to potential regulatory approval,” said Robert Garnick, PhD, head of regulatory affairs at Peregrine. “A global Phase III trial designed very similarly to the robust design of this Phase II trial greatly increases bavituximab’s likelihood of success.”

Audio Webcast
In conjunction with Dr. Gerber’s presentation in Chicago, Peregrine has posted an audio webcast and slide deck to Peregrine’s website. The webcast will be hosted by Joseph Shan, vice president of clinical and regulatory affairs. This event will be pre-recorded. Access to the audio and corresponding slides can be found on Peregrine’s website.

Conference Call
Peregrine will host a conference call and webcast to discuss these data and financial results for the first quarter fiscal year 2013 on Monday, September 10, 2012, at 11:00 AM ET (8:00 AM PT). To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call. A replay of the call will be available starting approximately two hours after the conclusion of the call through September 24, 2012 by calling (855) 859-2056, or (404) 537-3406 and using passcode 27367274.

About Lung Cancer
According to the American Cancer Society, lung cancer is the second most commonly diagnosed cancer in the U.S., with approximately 226,160 new cases and 160,340 deaths each year, representing approximately 28% of all cancer deaths. NSCLC is the most common type of lung cancer, accounting for approximately 85-90% of lung cancer cases. Unfortunately, the five-year survival rate for NSCLC patients is only 1%.

About Bavituximab
Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. Bavituximab is the lead drug candidate from the company’s PS technology platform and is currently being tested in eight clinical trials including three randomized Phase II trials in front-line and second-line non-small cell lung cancer, front-line pancreatic cancer and five investigator-sponsored trials (ISTs) in additional oncology indications.

PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but “flips” and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Safe Harbor Statement: Statements in this press release which are not purely historical, including statements regarding Peregrine Pharmaceuticals’ intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk that the overall survival data together with the above reported data may not support registration filings with the U.S. Food and Drug Administration, the risk that overall survival data from the planned Phase III trial will not be consistent with the results from the randomized, double-blind, placebo-controlled Phase IIb trial, the risk that results from the other randomized Phase II trial will not be consistent with results experienced in the earlier single-arm Phase II trial or support registration filings with the FDA, and the risk that Peregrine may not have or raise adequate financial resources to complete the planned clinical programs. Factors that could cause actual results to differ materially or otherwise adversely impact the company’s ability to obtain regulatory approval for its product candidates include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company’s SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2012. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

Image Available: http://www2.marketwire.com/mw/frame_mw?attachid=2086681

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com

Dataram (DRAM) Executes Agreement with AMD for Radeon RAMDisk

Dataram Corporation [NASDAQ: DRAM], a leading international manufacturer of computer memory, storage and software products, announced today that it has entered into a formal agreement with AMD (NYSE: AMD) to develop an AMD-branded version of Dataram’s popular RAMDisk software. Dataram will market the product under the name Radeon RAMDisk and will target gaming enthusiasts seeking exponential improvements in game load times leading to an enhanced gaming experience. AMD intends to offer special Radeon RAMDisk incentives for those purchasing AMD Value, Entertainment, Performance and Radeon Edition memory products.

With over four million downloads of RAMDisk occurring since its launch in 2000, Dataram’s RAMDisk software is recognized as a leader in the RAM drive software market. In addition to being used extensively by gaming enthusiasts, the software is also widely used for accelerating database access, speeding up internet browsing, substantially reducing video rendering times, reducing wear on SSDs and reducing software development cycles.

RAMDisk use has recently stirred great interest and expanded into corporate environments for accelerating specific applications and is being integrated into other commercially available products for which performance is critical. Quality and reliability, a hallmark of Dataram’s enterprise-grade memory products, is a key characteristic of its RAMDisk software that contributes to its exceptional recognition in the market.

“Dataram RAMDisk is one of the top RAMDisk software products in the Windows market. With the increase in memory capacity and reduced cost per gigabyte, now is the best time ever to utilize DRAM to create a lightning fast disk drive. Like all Dataram products, we have not only focused on speed and value, we have applied years of experience with data protection and reliability,” said Jason Caulkins, Dataram Chief Technologist.

Various benchmarks have shown that using RAMDisk results in up to 525% faster game load times, substantially improving the gaming experience. Used in conjunction with AMD memory products, gaming enthusiasts can gain distinct advantages when competing against their fellow gamers. Commenting on the launch of the AMD Radeon™ RAMDisk product in early fourth quarter, Roman Kyrychynskyi, Product Director at AMD said, “With the importance that memory plays in the overall PC experience, eliminating bottlenecks is crucial for avid PC gamers. Our collaboration with Dataram looks to provide the answer with an enhanced storage solution that reduces possible performance plateaus and provide a superior PC gaming experience.”

As RAMDisk continues to gain rapid consumer and commercial recognition, focus will be applied to rolling out the strategic product roadmap for RAMDisk. Particular focus will be directed towards expanding those markets that have already adopted and recognized the value of using Dataram’s RAMDisk.

About Dataram

Founded in 1967, Dataram is a worldwide leader in the manufacture of high-quality computer memory, storage and software products. Our products and services deliver IT infrastructure optimization, dramatically increase application performance and deliver substantial cost savings. Dataram solutions are deployed in 70 Fortune 100 companies and in mission-critical government and defense applications around the world. For more information about Dataram, visit www.dataram.com.

About AMD

AMD (NYSE: AMD) is a semiconductor design innovator leading the next era of vivid digital experiences with its groundbreaking AMD Accelerated Processing Units (APUs) that power a wide range of computing devices. AMD’s server computing products are focused on driving industry-leading cloud computing and virtualization environments. AMD’s superior graphics technologies are found in a variety of solutions ranging from game consoles, PCs to supercomputers. For more information, visit http://www.amd.com.

All names are trademarks or registered trademarks of their respective owners.

The information provided in this press release may include forward-looking statements relating to future events, such as the development of new products, pricing and availability of raw materials or the future financial performance of the Company. Actual results may differ from such projections and are subject to certain risks including, without limitation, risks arising from: changes in the price of memory chips, changes in the demand for memory systems, increased competition in the memory systems industry, order cancellations, delays in developing and commercializing new products and other factors described in the Company’s most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission, which can be reviewed at www.sec.gov.

Duma Energy (DUMA) Namibian Government Grants Exploration License on 5.3 Million Acre Concession

HOUSTON, Sept. 6, 2012 (GLOBE NEWSWIRE) — Duma Energy Corp. (OTCBB:DUMA) is pleased to announce that it has completed the share exchange agreement, dated August 7, 2012 (the “Agreement”) with Namibia Exploration, Inc. (“NEI”); the “Acquisition”. As a result of the completion of the Acquisition, NEI became a wholly owned subsidiary of Duma.

Duma, indirectly through NEI, has received a 39% working interest (43.33% cost responsibility) in an onshore African petroleum concession (the “Concession”) located in the Republic of Namibia which is approximately 5.3 million acres in size covered by Petroleum Exploration License No. 0038 issued by the Republic of Namibia Ministry of Mines and Energy. Duma holds its indirect working interest in the Concession in partnership with the National Petroleum Corporation of Namibia Ltd. (“NPC Namibia”) and Hydrocarb Namibia Energy Corporation (“Hydrocarb Namibia”), a company chartered in the Republic of Namibia and which is a majority owned subsidiary of Hydrocarb Corporation (“Hydrocarb”), a company organized under the laws of the State of Nevada, USA. Hydrocarb Namibia, as operator of the Concession, holds at 51% working interest (56.67% cost responsibility) in the Concession and NPC Namibia holds a 10% carried working interest in the Concession.

“The timely issuance of the concession license by the government of Namibia allows us now to begin focusing our efforts on the task of exploring our massive concession, which is roughly the size of the state of Massachusetts,” stated Jeremy G. Driver, Chairman and CEO of Duma Energy Corp. Driver added, “We are excited to move forward with the exploration phase in Namibia and are encouraged by the geological progress and findings so far.”

Pasquale Scaturro, Hydrocarb’s President and Chief Operating Officer stated, “There are few governments in Africa that can match the transparency and professionalism of Namibia. We are truly pleased to have such a large and premium concession located in an extremely prospective basin.”

Consulting Agreement with Hydrocarb

In conjunction with the closing of the Acquisition, Duma entered into a Consulting Services Agreement with Hydrocarb (the “Consulting Agreement”) whereby Hydrocarb will provide various consulting services with respect to Duma’s business ventures in Namibia and Hydrocarb acknowledges and agrees that the obligations of NEI under the Farm-in Opportunity Report between NEI and Hydrocarb (the “FOR”) will be satisfied in exchange for Duma paying a consulting fee (the “Fee”) to Hydrocarb of $2,400,000, payable over a 2 year period using either cash or restricted common shares of Duma.

Further information regarding the Acquisition, the Consulting Agreement, or the concession in Namibia may be found at the Company’s website at www.duma.com or by viewing the Company’s recent SEC filings.

About Duma Energy Corp.

Duma Energy Corp. (DUMA) is an aggressive growth company actively producing oil and gas in the continental United States, both on and offshore. Duma also has a significant interest in a 5.3-million acre concession in the Republic of Namibia in Southern Africa. Duma Energy will continue increasing revenue, cash flow, and reserves while pursuing aggressive growth through acquisition and participation in projects with the potential of providing exponential returns for shareholders. Further information can be found on the Company’s website at www.duma.com.

About Hydrocarb Corporation

Hydrocarb Corporation is a privately held energy exploration and production company targeting major under-explored oil and gas projects in emerging, highly prospective regions of the world. With headquarters in Houston, Texas, Hydrocarb maintains offices in Abu Dhabi, UAE and Windhoek, Namibia. For further information: www.hydrocarb.com

Safe Harbor Statements

Except for the statements of historical fact contained herein, the information presented in this news release constitutes “forward-looking statements” as such term is used in applicable United States laws. These statements relate to analyses and other information that are based on forecasts of future results, estimates of amounts not yet determinable and assumptions of management. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not always, using words or phrases such as “expects” or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans, “estimates” or “intends”, or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved) are not statements of historical fact and should be viewed as “forward-looking statements”. Such forward looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such risks and other factors include, among others, the actual results of exploration activities, variations in the underlying assumptions associated with the estimation or realization of oil or gas resources, the availability of capital to fund programs and the resulting dilution caused by the raising of capital through the sale of shares, accidents, labour disputes and other risks of the oil and gas industry including, without limitation, those associated with the environment, delays in obtaining governmental approvals, permits or financing or in the completion of development or construction activities, title disputes or claims limitations on insurance coverage. Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements contained in this news release and in any document referred to in this news release.

Forward looking statements are made based on management’s beliefs, estimates and opinions on the date the statements are made and the Company undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law. Such forward-looking statements reflect our current views with respect to future events and are subject to certain risks, uncertainties and assumptions, including, the risks and uncertainties outlined in our most recent financial statements and reports and registration statement filed with the United States Securities and Exchange Commission (the “SEC”) (available at www.sec.gov). Such risks and uncertainties may include, but are not limited to, the risks and uncertainties set forth in the Company’s filings with the SEC, such as the ability to obtain additional financing, the effect of economic and business conditions, the ability to attract and retain skilled personnel and factors outside the control of the Company. These forward-looking statements are made as of the date of this news release, and the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although the Company believes that the beliefs, plans, expectations and intentions contained in this news release are reasonable, there can be no assurance those beliefs, plans, expectations or intentions will prove to be accurate. Investors should consider all of the information set forth herein and should also refer to the risk factors disclosed in the Company’s periodic reports filed from time-to-time with the SEC.

This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

CONTACT: Investor Relations
Investor Awareness, Inc.
Tony Schor, 847-945-2222
www.InvestorAwareness.com

GlobalWise (GWIV) 8-K and Entry into a Material Definitive Agreement

Entry into a Material Definitive Agreement, Creation of a Direct Finan

Item 1.01. Entry into a Material Definitive Agreement.

On August 16, 2012, Intellinetics, Inc. (“Intellinetics”), the operating subsidiary of Globalwise Investments, Inc. and Alpharion Capital Partners (“Alpharion”) entered into a promissory note combination #1 agreement dated August 16, 2012, (the “Note Combination #1”) combining Alpharion Note #2, Alpharion Note #5, Alpharion Note #9, Alpharion Note #10, and Alpharion Note #11, (all such notes are hereinafter defined) with an aggregate principal amount of $118,556.39 and extending the due date of all such notes until September 30, 2012, without changing any other terms, The Note Combination #1 is filed as Exhibit 10.1 to this Current Report on Form 8-K. The summary of the terms of the Note Combination #1 contained herein is qualified in its entirety by reference such Exhibit 10.1.

On October 7, 2011, Intellinetics and Alpharion entered into a promissory note and subscription agreement dated October 7, 2011, in the principal amount of $7,500, at an interest rate of 3.25% (the “Alpharion Note #2”). The Alpharion Note #2 was due one hundred and eighty days from October 7, 2011. All past-due principal and accrued and past-due interest on the Alpharion Note #1 shall bear interest until paid at the rate of 3.25%. Pursuant to the Alpharion Note #2, the Company made certain customary representations, warranties and covenants. Payment of indebtedness under the Alpharion Note #2 may be accelerated upon a default in payment or in any of the terms, covenants, agreements, conditions or provisions of the Alpharion Note #2, if not cured pursuant to the terms therein, or in the event of any insolvency or bankruptcy of Intellinetics. The Alpharion Note #2 is filed as Exhibit 10.2 to this Current Report on Form 8-K. The summary of the terms of the Alpharion Note #2 contained herein is qualified in its entirety by reference such Exhibit 10.2.

On March 4, 2012, Intellinetics and Alpharion entered into a promissory note extension agreement dated March 4, 2012 (the “March 4, 2012 Extension Agreement”) extending the Alpharion Note #2 to a due date that is two hundred and seventy days from the October 7, 2011. All other provisions of Alpharion Note #2 were unchanged. The March 4, 2012 Extension Agreement is filed as Exhibit 10.3 to this Current Report on Form 8-K. The summary of the terms of the March 4, 2012 Extension Agreement contained herein is qualified in its entirety by reference such Exhibit 10.3.

On July 2, 2012, Intellinetics and Alpharion entered into a promissory note second extension agreement dated July 2, 2012 (the “July 2, 2012 Second Extension Agreement”) extending the Alpharion Note #2 to a due date that is three hundred fifteen days from the October 7, 2011. All other provisions of Alpharion Note #2 were unchanged. The July 2, 2012 Second Extension Agreement is filed as Exhibit 10.4 to this Current Report on Form 8-K. The summary of the terms of the July 2, 2012 Second Extension Agreement contained herein is qualified in its entirety by reference such Exhibit 10.4.

On November 21, 2011, Intellinetics and Alpharion entered into a promissory note and subscription agreement dated November 21, 2011, in the principal amount of $37,500, at an interest rate of 3.25% (the “Alpharion Note #5”). The Alpharion Note #5 was due one hundred and eighty days from November 21, 2011. All past-due principal and accrued and past-due interest on the Alpharion Note #5 shall bear interest until paid at the rate of 3.25%. Pursuant to the Alpharion Note #5, the Company made certain customary representations, warranties and covenants. Payment of indebtedness under the Alpharion Note #5 may be accelerated upon a default in payment or in any of the terms, covenants, agreements, conditions or provisions of the Alpharion Note #5, if not cured pursuant to the terms therein, or in the event of any insolvency or bankruptcy of Intellinetics. The Alpharion Note #5 is filed as Exhibit 10.5 to this Current Report on Form 8-K. The summary of the terms of the Alpharion Note #5 contained herein is qualified in its entirety by reference such Exhibit 10.5.

On May 13, 2012, Intellinetics and Alpharion entered into a promissory note extension agreement dated May 13,, 2012 (the “May 13, 2012 Extension Agreement”) extending the Alpharion Note #5 to a due date that is two hundred and seventy days from the November 21, 2011. All other provisions of Alpharion Note #5 were unchanged. The May 13, 2012 Extension Agreement is filed as Exhibit 10.6 to this Current Report on Form 8-K. The summary of the terms of the May 13, 2012 Extension Agreement contained herein is qualified in its entirety by reference such Exhibit 10.6.

On January 4, 2012, Intellinetics and Alpharion entered into a promissory note and subscription agreement dated January 4, 2012, in the principal amount of $13,556.39, at an interest rate of 3.25% (the “Alpharion Note #9”). The Alpharion Note #9 was due one hundred and eighty days from January 4, 2012. All past-due principal and accrued and past-due interest on the Alpharion Note #9 shall bear interest until paid at the rate of 3.25%. Pursuant to the Alpharion Note #9, the Company made certain customary representations, warranties and covenants. Payment of indebtedness under the Alpharion Note #9 may be accelerated upon a default in payment or in any of the terms, covenants, agreements, conditions or provisions of the Alpharion Note #9, if not cured pursuant to the terms therein, or in the event of any insolvency or bankruptcy of Intellinetics. The Alpharion Note #9 is filed as Exhibit 10.7 to this Current Report on Form 8-K. The summary of the terms of the Alpharion Note #9 contained herein is qualified in its entirety by reference such Exhibit 10.7.

On July 1, 2012, Intellinetics and Alpharion entered into a promissory note extension agreement dated July 1, 2012 (the “July 1, 2012 Extension Agreement”) extending the Alpharion Note #9 to a due date that is two hundred and twenty five days from the January 4, 2011. All other provisions of Alpharion Note #9 were unchanged. The July 1, 2012 Extension Agreement is filed as Exhibit 10.8 to this Current Report on Form 8-K. The summary of the terms of the July 1, 2012 Extension Agreement contained herein is qualified in its entirety by reference such Exhibit 10.8.

On January 9, 2012, Intellinetics and Alpharion entered into a promissory note and subscription agreement dated January 9, 2012, in the principal amount of $10,000, at an interest rate of 3.25% (the “Alpharion Note #10”). The Alpharion Note #10 was due one hundred and eighty days from January 9, 2012. All past-due principal and accrued and past-due interest on the Alpharion Note #10 shall bear interest until paid at the rate of 3.25%. Pursuant to the Alpharion Note #10, the Company made certain customary representations, warranties and covenants. Payment of indebtedness under the Alpharion Note #10 may be accelerated upon a default in payment or in any of the terms, covenants, agreements, conditions or provisions of the Alpharion Note #10, if not cured pursuant to the terms therein, or in the event of any insolvency or bankruptcy of Intellinetics. The Alpharion Note #10 is filed as Exhibit 10.9 to this Current Report on Form 8-K. The summary of the terms of the Alpharion Note #9 contained herein is qualified in its entirety by reference such Exhibit 10.9.

On July 6, 2012, Intellinetics and Alpharion entered into a promissory note extension agreement dated July 6, 2012 (the “July 6, 2012 Extension Agreement”) extending the Alpharion Note #10 to a due date that is two hundred and twenty five days from the January 6, 2011. All other provisions of Alpharion Note #10 were unchanged. The July 6, 2012 Extension Agreement is filed as Exhibit 10.10 to this Current Report on Form 8-K. The summary of the terms of the July 6, 2012 Extension Agreement contained herein is qualified in its entirety by reference such Exhibit 10.10.

On January 19, 2012, Intellinetics and Alpharion entered into a promissory note and subscription agreement dated January 19, 2012, in the principal amount of $50,000, at an interest rate of 3.25% (the “Alpharion Note #11”). The Alpharion Note #11 was due one hundred and eighty days from January 19, 2012. All past-due principal and accrued and past-due interest on the Alpharion Note #11 shall bear interest until paid at the rate of 3.25%. Pursuant to the Alpharion Note #10, the Company made certain customary representations, warranties and covenants. Payment of indebtedness under the Alpharion Note #11 may be accelerated upon a default in payment or in any of the terms, covenants, agreements, conditions or provisions of the Alpharion Note #11, if not cured pursuant to the terms therein, or in the event of any insolvency or bankruptcy of Intellinetics. The Alpharion Note #11 is filed as Exhibit 10.11 to this Current Report on Form 8-K. The summary of the terms of the Alpharion Note #9 contained herein is qualified in its entirety by reference such Exhibit 10.11.

On July 16, 2012, Intellinetics and Alpharion entered into a promissory note extension agreement dated July 16, 2012 (the “July 16, 2012 Extension Agreement”) extending the Alpharion Note #11 to a due date that is two hundred and twenty five days from the January 16, 2011. All other provisions of Alpharion Note #11 were unchanged. The July 16, 2012 Extension Agreement is filed as Exhibit 10.12 to this Current Report on Form 8-K. The summary of the . . .

Item 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

On August 16, 2012, Intellinetics and Alpharion entered into the Note Combination #1. The terms of the Note Combination #1 are described in Item 1.01 of this Current Report on Form 8-K, which description is incorporated herein by reference.

On September 2, 2012, Intellinetics and Alpharion entered into the Note Combination #2. The terms of the Note Combination #2 are described in Item 1.01 of this Current Report on Form 8-K, which description is incorporated herein by reference.

On September 2, 2012, Intellinetics and Alpharion entered into the Note Combination #3. The terms of the Note Combination #3 are described in Item 1.01 of this Current Report on Form 8-K, which description is incorporated herein by reference.

On September 2, 2012, Intellinetics and Alpharion entered into the Note Combination #4. The terms of the Note Combination #4 are described in Item 1.01 of this Current Report on Form 8-K, which description is incorporated herein by reference.

On September 2, 2012, Intellinetics and Alpharion entered into the Note Combination #5. The terms of the Note Combination #5 are described in Item 1.01 of this Current Report on Form 8-K, which description is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Name of Exhibit

10.1* Promissory note combination #1 agreement dated August 16, 2012, by and
among Intellinetics and Alpharion combining Alpharion Note #2, Alpharion
Note #5, Alpharion Note #9, Alpharion Note #10, and Alpharion Note #11,
with an aggregate principal amount of $118,556.39 and extending the due
date of all such notes until September 30, 2012.
10.2* Promissory note and subscription agreement dated October 7, 2011, by and
among Intellinetics and Alpharion in the principal amount of $7,500.
10.3* Promissory note extension agreement dated March 4, 2012 by and among
Intellinetics and Alpharion.
10.4* Promissory note second extension agreement dated July 2, 2012 by and
among Intellinetics and Alpharion.
10.5* Promissory note and subscription agreement dated November 21, 2011, by
and among Intellinetics and Alpharion in the principal amount of
$37,500.
10.6* Promissory note extension agreement dated May 13,, 2012 by and among
Intellinetics and Alpharion.
10.7* Promissory note and subscription agreement dated January 4, 2012, by and
among Intellinetics and Alpharion in the principal amount of
$13,556.39.
10.8* Promissory note extension agreement dated July 1, 2012 by and among
Intellinetics and Alpharion.
10.9* Promissory note and subscription agreement dated January 9, 2012, by
and among Intellinetics and Alpharion in the principal amount of
$10,000, at an interest rate of 3.25%.
10.10* Promissory note extension agreement dated July 6, 2012 by and among
Intellinetics and Alpharion.
10.11* Promissory note and subscription agreement dated January 19, 2012, by
and among Intellinetics and Alpharion in the principal amount of
$50,000.
10.12* Promissory note extension agreement dated July 16, 2012 by and among
Intellinetics and Alpharion.
10.13* Promissory note combination #2 agreement dated September 2, 2012, (the
“Note Combination #2”) by and among Intellinetics and Alpharion
combining Alpharion Note #1, Alpharion Note #3, Alpharion Note #7, and
Alpharion Note #15 with an aggregate principal amount of $115,000 and
extending the due date of all such notes until November 16, 2012.
10.14* Promissory note and subscription agreement dated September 8, 2011, in
the principal amount of $17,500, by and among Intellinetics and
Alpharion.
10.15* Promissory note extension agreement dated March 6, 2012 by and among
Intellinetics and Alpharion.
10.16* Promissory note and subscription agreement dated November 1, 2011, in
the principal amount of $7,500,. by and among Intellinetics and
Alpharion
10.17* Promissory note extension agreement dated May 7, 2012 by and among
Intellinetics and Alpharion.
10.18* Promissory note second extension agreement dated July 27, 2012 by and
among Intellinetics and Alpharion.
10.19* Promissory note and subscription agreement dated December 7, 2011, in
the principal amount of $80,000, by and among Intellinetics and
Alpharion.
10.20* Promissory note extension agreement dated June 4, 2012 by and among
Intellinetics and Alpharion.
10.21* Promissory note and subscription agreement dated February 14, 2012, in
the principal amount of $10,000, by and among Intellinetics and
Alpharion.
10.22* Promissory note extension agreement dated August 11, 2012 by and among
Intellinetics and Alpharion.
10.23* Promissory note combination #3 agreement dated September 2, 2012, (the
“Note Combination #3”) by and among Intellinetics and Alpharion
combining Alpharion Note #8, Alpharion Note #18, with an aggregate
principal amount of $119,000 and extending the due date of all such
notes until November 16, 2012.
10.24* Promissory note and subscription agreement dated December 9, 2011, in
the principal amount of $15,000, by and among Intellinetics and
Alpharion.
10.25* Promissory note extension agreement dated June 6, 2012 by and among
Intellinetics and Alpharion.
10.26* Promissory note and subscription agreement dated March 9, 2012, in the
principal amount of $104,000, by and among Intellinetics and Alpharion.
10.27* Promissory note combination #4 agreement dated September 2, 2012, (the
“Note Combination #4”) by and among Intellinetics and Alpharion
combining Alpharion Note #12, Alpharion Note #14, Alpharion Note #19,
and Alpharion Note #20 with an aggregate principal amount of $111,500.
10.28* Promissory note and subscription agreement dated January 27, 2012, in
the principal amount of $5,000, by and among Intellinetics and
Alpharion.

10.29* Promissory note extension agreement dated July 24, 2012 by and among
Intellinetics and Alpharion.
10.30* Promissory note and subscription agreement dated February 10, 2012, in
the principal amount of $85,000,. by and among Intellinetics and
Alpharion.
10.31* Promissory note extension agreement dated July 24, 2012 by and among
Intellinetics and Alpharion.
10.32* Promissory note and subscription agreement dated March 14, 2011, in the
principal amount of $15,000, by and among Intellinetics and Alpharion.
10.33* Promissory note and subscription agreement dated March 15, 2011, in the
principal amount of $6,500, by and among Intellinetics and Alpharion.
10.34* Promissory note combination #5 agreement dated September 2, 2012, by and
among Intellinetics and Alpharion.
10.35* Promissory note and subscription agreement dated January 31, 2012, in
the principal amount of $35,000, by and among Intellinetics and
Alpharion.
10.36* Promissory note extension agreement dated July 28, 2012 by and among
Intellinetics and Alpharion.
10.37* Promissory note and subscription agreement dated February 15, 2012, by
and among Intellinetics and Alpharion.
10.38* Promissory note extension agreement dated August 12, 2012 by and among
Intellinetics and Alpharion.

VistaGen Therapeutics (VSTA) Announces Strategic Financing With Platinum Long Term Growth Fund

SOUTH SAN FRANCISCO, CA — (Marketwire) — 09/06/12 — VistaGen Therapeutics, Inc. (OTCBB: VSTA) (OTCQB: VSTA), a biotechnology company applying stem cell technology for drug rescue and novel pharmaceutical assays for predictive heart and liver toxicology and drug metabolism screening, today announced that Platinum Long Term Growth VII, LLC (Platinum) purchased a $750,000 secured convertible promissory note from the Company, supplementing its purchase in July 2012 of a similar note in the principal amount of $500,000. VistaGen currently anticipates that all amounts due under the two notes will be rolled into a proposed financing by Platinum expected to result in gross proceeds to VistaGen of at least $3.25 million, including $1.25 million from the two outstanding notes.

In addition, VistaGen announced the strategic restructuring of approximately $2.38 million of long-term indebtedness to Morrison & Foerster LLP (M&F), its intellectual property counsel. The restructuring is expected to result in VistaGen’s issuance of restricted common stock to M&F, at a price of $1.00 per share, as payment for approximately $1.38 million of the principal amount of such long-term indebtedness.

“We are very pleased with these recent endorsements from our largest institutional investor and our highly-regarded, long-time intellectual property counsel,” stated Shawn K. Singh, CEO of VistaGen Therapeutics. “Their confidence in our team and stem cell technology platform is a key component of the foundation underlying our core drug rescue, predictive toxicology and drug metabolism screening initiatives.”

Further information regarding VistaGen’s recent financing and debt restructuring transactions with Platinum Long Term Growth Fund and Morrison & Foerster, respectively, is set forth in the Company’s Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (SEC) and available on both the SEC’s website at www.sec.gov and the Company’s website at www.VistaGen.com.

About VistaGen Therapeutics

VistaGen is a biotechnology company applying human pluripotent stem cell technology for drug rescue and novel pharmaceutical assays for predictive heart and liver toxicology and drug metabolism screening. VistaGen’s drug rescue activities are focused on combining its human pluripotent stem cell technology platform, Human Clinical Trials in a Test Tube™, with modern medicinal chemistry to generate new chemical variants (Drug Rescue Variants) of once-promising small-molecule drug candidates. These are drug candidates discontinued due to heart or liver toxicity after substantial development by large pharmaceutical companies, the U.S. National Institutes of Health (NIH) or university laboratories. VistaGen uses its pluripotent stem cell technology to generate early indications, or predictions, of how humans will ultimately respond to new drug candidates before they are ever tested in humans, bringing human biology to the front end of the drug development process.

Additionally, VistaGen’s orally-available, small molecule drug candidate, AV-101, is completing Phase 1b development for treatment of neuropathic pain. Neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system, affects approximately 1.8 million people in the U.S. alone. VistaGen is currently exploring strategic partnering opportunities to leverage its current Phase 1 clinical program and enable Phase 2 clinical development of AV-101 for neuropathic pain, depression and potentially other neurological diseases or conditions. To date, VistaGen has been awarded over $8.5 million from the NIH for development of AV-101.

Visit VistaGen at http://www.VistaGen.com, follow VistaGen at http://www.twitter.com/VistaGen or view VistaGen’s Facebook page at http://www.facebook.com/VistaGen.

Cautionary Statement Regarding Forward-Looking Statements
The statements in this press release that are not historical facts may constitute forward-looking statements that are based on current expectations and are subject to risks and uncertainties that could cause actual future results to differ materially from those expressed or implied by such statements. Those risks and uncertainties include, but are not limited to, risks related to the successful completion of the Company’s ongoing clinical studies involving AV-101, the failure of the Company’s future drug rescue programs involving its stem cell technology-based Human Clinical Trial in a Test Tube™ platform, the Company’s ability to enter into third-party drug rescue collaborations, risks and uncertainties relating to the availability of substantial additional capital from Platinum or any other investor to support the Company’s research, development and commercialization activities, and the success of its research and development plans and strategies, including plans and strategies related to AV-101 and any drug rescue variant identified and developed by VistaGen. These and other risks and uncertainties are identified and described in more detail in VistaGen’s filings with the Securities and Exchange Commission (SEC). These filings are available on the SEC’s website at www.sec.gov. VistaGen undertakes no obligation to publicly update or revise any forward-looking statements.

For More Information:
Shawn K. Singh, J.D.
Chief Executive Officer
VistaGen Therapeutics, Inc.
www.VistaGen.com
650-244-9990 x224
Investor.Relations@VistaGen.com

Mission Investor Relations
Atlanta, Georgia
http://www.MissionIR.com
404-941-8975
Investors@MissionIR.com

Orexigen Therapeutics (OREX) announces continued rapid enrollment into the Light Study

SAN DIEGO, Sept. 5, 2012 /PRNewswire/ — Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced an update to the projected timeframe for enrollment of patients in the Light Study, the cardiovascular outcomes clinical trial evaluating Contrave® (naltrexone SR/ bupropion SR). Enrollment into the study has continued without abatement at a rate faster than originally expected, with more than 4,500 patients enrolled as of August 31. Orexigen now expects to close enrollment to new patients in the fourth quarter of 2012.

The primary endpoint of the Light Study is the time to occurrence of major adverse cardiovascular events (MACE) during randomized treatment for Contrave compared to placebo. After at least 87 MACE have been adjudicated, the study’s independent Data Monitoring Committee will conduct an interim analysis. If the interim analysis excludes a doubling of risk of MACE in patients receiving Contrave compared to placebo, Orexigen plans to resubmit the Contrave New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for approval. The exclusion of a doubling of risk of MACE was established as the threshold for approvability of Contrave during discussions with the FDA prior to the start of the Light Study.

“By successfully expediting patient enrollment into the Light Study, we are executing on our promise to shareholders to do what we can to pull forward the time to the interim analysis,” said Michael Narachi, CEO of Orexigen.

“The other key information needed to determine the timing of the interim analysis is the rate of MACE in the study, which is still too early to know,” Narachi continued. “Importantly, because the demographics of the patient population entering the study are in line with our targets for age, gender, race, smoking status, prevalence of cardiovascular disease and other co-morbidities, we remain confident that we will have the requisite number of events needed to conduct the interim analysis in 2013. We would expect to update investors with a more precise estimate of the timing of the interim analysis after we have received sufficient information about the rate of events from the Data Monitoring Committee.”

As a result of the successful acceleration of enrollment, some expenses associated with the Light Study will shift from 2013 into 2012. Accelerating enrollment does not result in a change to the Company’s guidance that current cash, cash equivalents and marketable securities will last through the anticipated timing of the resubmission of the Contrave NDA.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company’s lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company’s other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at www.orexigen.com.

Forward-Looking Statements

Orexigen cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “indicates,” “will,” “intends,” “potential,” “suggests,” “assuming,” “designed” and similar expressions are intended to identify forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These forward-looking statements include statements regarding the timing of patient enrollment and MACE events in the Light Study; the ability to enroll the targeted patient population; the ability to activate sites and conduct the Light Study; the potential for, and timing of, the accrual and adjudication of MACE events and the potential resubmission of the Contrave NDA; the safety and effectiveness of Contrave; the potential for, and timing of, approval for Contrave and that the Company’s cash, cash equivalents and marketable securities will last through the anticipated timing of the resubmission of the Contrave NDA. The inclusion of forward-looking statements should not be regarded as a representation by Orexigen that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the Orexigen business, including, without limitation: the Special Protocol Assessment (SPA) is not binding on the FDA if public health concerns unrecognized at the time the SPA agreement was entered into become evident, other new scientific concerns regarding product safety or efficacy arise, or if Orexigen fails to comply with the agreed upon trial protocol; Orexigen’s ability to conduct the Light Study and the progress and timing thereof, including risks associated with recruiting and enrolling patients in the Light Study; Orexigen’s ability to demonstrate in the Light Study that the risk of MACE in overweight and obese subjects treated with Contrave does not adversely affect the product candidate’s benefit-risk profile; the potential that earlier clinical trials may not be predictive of future results in the Light Study; the potential for the FDA to not approve Contrave even after the resubmission with the MACE event data; the potential for the Light Study to cost more than what is projected; the potential for early termination of the collaboration agreement between Orexigen and Takeda; the costs and time required to complete additional clinical, non-clinical or other requirements prior to any resubmission of an NDA; the therapeutic and commercial value of Contrave; Orexigen’s ability to maintain sufficient capital; and other risks described in the Company’s filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Orexigen undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading “Risk Factors” in Orexigen’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission August 9, 2012 and which is available from the SEC’s website (www.sec.gov) and on Orexigen’s website (www.orexigen.com) under the heading “Investor Relations.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Orexigen Contact:

Media Contact:

McDavid Stilwell

Denise Powell

VP, Corporate Communications and Business Development

WCG

(858) 875-8629

(510) 703-9491

Gold Standard (GSV) Announces Appointment of New Independent Director

VANCOUVER, BRITISH COLUMBIA — (Marketwire) — 09/05/12 — Gold Standard Ventures Corp. (TSX VENTURE:GSV)(NYSE MKT:GSV)(NYSE Amex:GSV) (“Gold Standard” or the “Company”) (www.goldstandardv.com) has appointed Jamie Strauss to its Board as an independent director.

Mr. Strauss is currently a Director of a boutique mining finance firm, Strauss Partners, based in London, England. Jamie has worked as a stockbroker in the City of London for 25 years, specialising in the corporate resource arena, including a term as Managing Director of UK for BMO Capital Markets 2007-2009. He has raised in excess of $1bn in recent years for projects spanning the globe in both the energy and mineral world on behalf of leading institutions in North America, Australia and Europe. He has been a committee member of the Association of Mining Analysts for the last four years, and is a non-executive director of Wildhorse Energy Ltd. and Altius Minerals. Jamie was, until recently, a director of Extorre Gold Mines Ltd. until it was taken over by Yamana.

“Mr. Strauss brings over 25 years of mining sector experience in capital markets and should help strengthen Gold Standard’s presence in Europe. We are extremely pleased to welcome him to our Board,” said Jonathan Awde, a director and chief executive officer of Gold Standard Ventures.

The Company also announces that, pursuant to its stock option incentive plan, it has granted director incentive stock options to purchase 150,000 common shares of the company at today’s closing price for a period of 5 years.

The stock options are subject to the terms of the Company’s stock option plan and regulatory approval.

ABOUT GOLD STANDARD VENTURES – Gold Standard is a Canadian-based company focused on the acquisition and exploration of district-scale and other gold-bearing mineral properties exclusively in the State of Nevada, United States. The Company’s flagship property is the Railroad Project, located in Elko County, Nevada. The Railroad Project is a prospective gold exploration target comprising approximately 19,764 acres (30.8 square miles) within the Carlin Trend of north-central Nevada.

On behalf of the Board of Directors of Gold Standard,

Jonathan Awde, President and Director

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This news release contains forward-looking statements, which relate to future events or future performance and reflect management’s current expectations and assumptions. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to the Company. All statements, other than statements of historical fact, included herein including, without limitation, statements about the intended use of proceeds from the Offering are forward looking statements. By their nature, forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements, or other future events, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following risks: operational risks associated with mineral exploration; fluctuations in commodity prices; title matters; and the additional risks identified in our filings with Canadian securities regulators on SEDAR in Canada (available at www.sedar.com) and with the SEC on EDGAR (available at www.sec.gov/edgar.shtml). These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, the Company does not assume any obligation to update or revise them to reflect new events or circumstances.

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) nor the NYSE MKT accepts responsibility for the adequacy or accuracy of this news release.

Contacts:
Gold Standard Ventures Corp.
Jonathan Awde
President
604-669-5702
info@goldstandardv.com
www.goldstandardv.com

Progenitor (NBS) a NeoStem Company, Invited to Present at Two Conferences

NEW YORK, Sept. 5, 2012 (GLOBE NEWSWIRE) — NeoStem, Inc. (NYSE:NBS) (“NeoStem” or the “Company”), a cell therapy company, today announced that Company management of a NeoStem company, Progenitor Cell Therapy (“PCT”), an internationally recognized contract development and manufacturing organization (CDMO), has been invited to present on its core expertise in development of commercial manufacturing processes for cell therapy at two cell therapy conferences in September. At each, PCT will offer its unique perspective as an industry leader in contract development and manufacturing of cell therapy products, with over 12 years of exclusive cell-therapy focused experience.

Timothy Fong, Ph.D, M.B.A, PCT’s Vice President, Technology and Product Development, will be sharing PCT’s expertise in cell therapy manufacturing with a focus on commercialization. At IBC Life Sciences’ Cell Therapy Bioprocessing Conference, he will chair a panel on quality assurance and controls and will give a presentation entitled “From Concept to Product: Considerations for Developing a Robust Commercial Manufacturing Process”, which will include considerations for developing a robust commercial manufacturing process. He will also speak at the Stem Cells USA and Regenerative Medicine Congress on “Cell manufacturing considerations for first-in-world stem cell therapeutics”.

Dr. Fong stated, “As a cell therapeutic progresses from concept to product, the development of a commercial manufacturing process may contain unexpected technical and quality issues. The development path should follow several defined steps. My presentations will discuss the key steps in the process and highlight critical areas that need to be addressed to develop a successful commercial manufacturing process. PCT helps clients bridge the gap between discovery and patient care through efficient transfer of cell-based therapies from laboratory into clinical practice.”

NeoStem and PCT invite you to attend the conference(s), see Dr. Fong’s talks, and connect with the PCT team at PCT’s booths. If you are a colleague of PCT or NeoStem, PCT can offer you a registration discount. Please contact PCT at bdm@pctcelltherapy.com for more details.

IBC Life Sciences’ 2nd Annual Cell Therapy Bioprocessing Conference

Date: September 12, 2012, 3:30 PM EDT
Venue: DoubleTree Crystal City Hotel, Arlington, VA
Presenter: Timothy Fong, Ph.D., M.B.A., PCT’s Vice President, Technology and Product Development

Terrapinn 4th Annual Stem Cells USA and Regenerative Medicine Congress

Date: September 21, 2012, 11:30 AM EDT
Venue: The Charles Hotel, Boston, MA
Presenter: Timothy Fong, Ph.D., M.B.A., PCT’s Vice President, Technology and Product Development

About NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a large role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market leading company in this fast developing cell therapy market. Our multi-faceted business strategy combines a state-of-the-art contract development and manufacturing subsidiary, Progenitor Cell Therapy, LLC (“PCT”) with a medically important cell therapy product development program, enabling near and long-term revenue growth opportunities. We believe this expertise and existing research capabilities and collaborations will enable us to achieve our mission of becoming a premier cell therapy company.

Our contract development and manufacturing service business supports the development of proprietary cell therapy products. NeoStem’s most clinically advanced therapeutic, AMR-001, is being developed at Amorcyte, LLC (“Amorcyte”), which we acquired in October 2011. Amorcyte is developing a cell therapy for the treatment of cardiovascular disease and is enrolling patients in a Phase 2 trial to investigate AMR-001’s efficacy in preserving heart function after a heart attack. Athelos Corporation (“Athelos”), which is approximately 80%-owned by our subsidiary, PCT, is collaborating with Becton-Dickinson in the early clinical exploration of a T-cell therapy for autoimmune conditions. In addition, pre-clinical assets include our VSELTM Technology platform as well as our mesenchymal stem cells product candidate for regenerative medicine. Our service business and pipeline of proprietary cell therapy products work in concert, giving us a competitive advantage that we believe is unique to the biotechnology and pharmaceutical industries. Supported by an experienced scientific and business management team and a patent and patent pending (IP) portfolio, we believe we are well positioned to succeed.

For more information on NeoStem, please visit www.neostem.com. For more information on PCT, please visit www.pctcelltherapy.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements reflect management’s current expectations, as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the successful execution of the Company’s business strategy, including with respect to the Company’s or its partners’ successful development of AMR-001 and other cell therapeutics, the size of the market for such products, its competitive position in such markets, the Company’s ability to successfully penetrate such markets and the market for its CDMO business, and the efficacy of protection from its patent portfolio, as well as the future of the cell therapeutics industry in general, including the rate at which such industry may grow. Forward looking statements also include statements with respect to satisfying all conditions to closing the disposition of Erye, including receipt of all necessary regulatory approvals in the PRC. The Company’s actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors, including but not limited to (i) the Company’s ability to manage its business despite operating losses and cash outflows, (ii) its ability to obtain sufficient capital or strategic business arrangement to fund its operations, including the clinical trials for AMR-001, (iii) successful results of the Company’s clinical trials of AMR-001 and other cellular therapeutic products that may be pursued, (iv) demand for and market acceptance of AMR-001 or other cell therapies if clinical trials are successful and the Company is permitted to market such products, (v) establishment of a large global market for cellular-based products, (vi) the impact of competitive products and pricing, (vii) the impact of future scientific and medical developments, (viii) the Company’s ability to obtain appropriate governmental licenses and approvals and, in general, future actions of regulatory bodies, including the FDA and foreign counterparts, (ix) reimbursement and rebate policies of government agencies and private payers, (x) the Company’s ability to protect its intellectual property, (xi) the company’s ability to successfully divest its interest in Erye, and (xii) matters described under the “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 20, 2012 and in the Company’s other periodic filings with the Securities and Exchange Commission, all of which are available on its website. The Company does not undertake to update its forward-looking statements. The Company’s further development is highly dependent on future medical and research developments and market acceptance, which is outside its control.

CONTACT: Trout Group
Gitanjali Jain Ogawa, Vice President
Phone: +1-646-378-2949
Email: gogawa@troutgroup.com

TeleCommunication Systems (TSYS) Awardee on $2.6B Custom SATCOM Solutions IDIQ Contract

Department of Defense and Federal Civilian Agencies Now Able to Purchase End-to-End, Innovative Products, Services and Highly Reliable Connectivity

ANNAPOLIS, Md., Sept. 5, 2012 /PRNewswire/ — TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS), a world leader in highly reliable and secure mobile communication technology, today announced it has been selected as one of eight awardees of the Custom SATCOM Solutions (CS2) contract. This contract enables the Department of Defense (DoD) and federal civilian agencies to purchase TCS end-to-end, turnkey solutions which incorporate commercial satellite communication services through both the General Services Administration (GSA) and the Defense Information Systems Agency (DISA). The multiple-awardee, Indefinite Delivery – Indefinite Quantity (IDIQ) contract, with an estimated ceiling of $2.6 billion over five years, is part of the Future Commercial Satellite Communications Services Acquisition (FCSA) strategy established by the GSA and DISA to consolidate transponded capacity (satellite bandwidth), subscription services (including terminal and bandwidth combinations) and end-to-end solutions contracting vehicles into one program for procuring custom satellite communication solutions from a select group of qualified contractors.

Government and defense organizations are increasing their reliance on commercial satellite technology to provide essential, secure communications to the warfighter, command and control functions, and disaster recovery and response teams. According to Northern Sky Research, the global market for commercial government satellite equipment and services will grow from $4 billion in 2011 to $9.2 billion in 2019. The need for flexible, mobile wireless services drives agencies toward industry leaders like TCS and its partners for state-of-the-art solutions to reliably and securely transmit voice, video and data across the globe. TCS has a 25-year history of providing proven, reliable and cost-effective secure communication solutions for all tiers of government, and this award will broaden access by government agencies to that experience.

Supporting Quote:

TCS Senior Vice President and General Manager of Government Solutions, Michael Bristol said, “This award significantly expands TCS access to business opportunities well-suited to TCS TotalCom solutions. For the next several years, CS2 will be the main contract vehicle for the DoD and federal civilian agencies to purchase commercial satcom solutions. This contract vehicle aligns perfectly with our business model. We are a value-added systems integrator that provides mission-critical Total Communication Solutions consisting of deployable satcom equipment, managed satcom network services and field support staff.”

For the past 25 years, TCS has established a proven track record as a trusted provider of communication technology solutions to solve the government’s toughest technical challenges, under conditions that demand the highest level of reliability, availability and security. To ensure mission continuity, TCS TotalCom™ offers deployable, highly secure communication solutions and complete end-to-end managed services for converged (IP-based) voice, video and data solutions to organizations requiring seamless and secure connectivity between fixed sites and remote operations.

About TeleCommunication Systems, Inc.

TeleCommunication Systems, Inc. (TCS) (NASDAQ: TSYS) is a world leader in highly reliable and secure mobile communication technology. TCS infrastructure forms the foundation for market leading solutions in E9-1-1, text messaging, commercial location and deployable wireless communications. TCS is at the forefront of new mobile cloud computing services providing wireless applications for navigation, hyper-local search, asset tracking, social applications and telematics. Millions of consumers around the world use TCS wireless apps as a fundamental part of their daily lives. Government agencies utilize TCS’ cyber security expertise, professional services, and highly secure deployable satellite solutions for mission-critical communications. Headquartered in Annapolis, MD, TCS maintains technical, service and sales offices around the world. To learn more about emerging and innovative wireless technologies, visit www.telecomsys.com.

Except for the historical information contained herein, this news release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended. These statements are subject to risks and uncertainties and are based upon TCS’ current expectations and assumptions that if incorrect would cause actual results to differ materially from those anticipated. Risks include without limitation the possibility that TCS will not win task orders under the contract, that orders do not get fully funded, and those detailed from time to time in the Company’s SEC reports, including the reports on Form 10-K for the year ended December 31, 2011, and on Form 10-Q for the quarter ended June 30, 2012.

Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to update or revise the information in this press release, whether as a result of new information, future events or circumstances, or otherwise.

(Logo: http://photos.prnewswire.com/prnh/20120503/PH99996LOGO )

Company Contact:

Media Contact:

Investor Relations:

TeleCommunication Systems, Inc.

Nadel Phelan, Inc.

Liolios Group, Inc.

Meredith Allen

Graham Sorkin

Scott Liolios

410-295-1865

831-440-2406

949-574-3860

MAllen@telecomsys.com

graham@nadelphelan.com

info@liolios.com

SOURCE TeleCommunication Systems, Inc.

SEFE (SEFE) CEO Don Johnston Featured on theStockRadio.com

BOULDER, CO — (Marketwire) — 09/05/12 — SEFE, Inc. (OTCBB: SEFE) (OTCQB: SEFE) (the “Company”), a sustainability company engaged in offering innovative, pioneering solutions for the world’s energy needs, today announced that theStockRadio.com has posted an audio interview recently conducted with Chief Executive Officer, Don Johnston.

To access the interview, visit http://thestockradio.com/donald-johnston-ceo-of-sefe-inc-otcsefe/1316.

Mr. Johnston introduced listeners to the company and reviewed its business strategy, technologies and patents, and current initiatives. He also discussed the science behind the Harmony III atmospheric energy system, progress with ongoing testing and development, and future plans.

About SEFE, Inc.

SEFE focuses on pushing the boundaries of what’s possible, embracing innovation and employing the cutting-edge to solve problems, and offering sustainable solutions to a world hungry for invention, direction and leadership. SEFE is technology- and solutions-driven, focusing on developing inventions that provide a real-world impact and true profitability. So, success is measured by both a sustainable return on investment, as well as a project’s sustainability from an environmental perspective.

For more information, visit www.SEFElectric.com.

About theStockRadio.com

theStockRadio.com, a small-cap research and investment commentary provider, strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. Moreover, theStockRadio.com provides investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them.

For more information, visit www.thestockradio.com.

Forward-Looking Statements
This release, and the interview on theStockRadio.com referenced herein, include “forward-looking statements” as defined by the SEC. Any statements in this news release, referenced interviews and on our website and youtube page that are not historical facts are forward-looking statements that involve risks and uncertainties. Words such as “estimate,” “expect,” “would,” “target,” “goal,” “potential,” and forms of those words and others indicate forward-looking statements. These statements are based on certain assumptions made by the Company based on management’s experience and perception of historical trends, current conditions, anticipated future developments and other factors believed to be appropriate. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause actual results to differ materially from those implied or expressed by the forward-looking statements. Further information on our business are discussed in the Company’s filings with the SEC, including its Annual Report on Form 10-K under the headings “Business” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Our business is subject to various risks and uncertainties, including those described in our Registration Statement on Form 10 filed with the SEC, under the heading “Risk Factors.”

Contact:
SEFE, Inc.
Justin Ackerman
714-495-1927
ir@sefelectric.com

Mission Investor Relations
404-941-8975
Investors@MissionIR.com
www.MissionIR.com

Ocean Power Technologies (OPTT) to Work with U.S. Department of Homeland Security

Ocean Power Technologies to Work with U.S. Department of Homeland Security and Wins New Autonomous PowerBuoy Grant

Ocean Power Technologies, Inc. (Nasdaq: OPTT) (“OPT” or “the Company”) today announced that it has entered into a Cooperative Research and Development Agreement (“CRADA”) with the U.S. Department of Homeland Security (“DHS”) Science & Technology Directorate (“S&T”) to perform a new round of in-ocean tests on its Autonomous PowerBuoy® to further demonstrate its use for ocean surveillance.

Specifically, the DHS S&T Borders and Maritime Security Division will collaborate with OPT to demonstrate the effectiveness of its long duration maritime vessel detection platform. This will involve the redeployment of an APB-350 Autonomous PowerBuoy off the coast of New Jersey, where previous work through the U.S. Navy’s Littoral Expeditionary Autonomous PowerBuoy (“LEAP”) program last year produced extremely positive results, including higher-than-predicted power harvesting capability and survivability during Hurricane Irene and its 50-foot high waves.

In tandem with the CRADA, OPT has been awarded a new $75,000 grant from the Maryland Technology Development Corporation (“MTDC”) via a joint technology transfer initiative to show how the Autonomous PowerBuoy can be used with multiple surveillance technologies. OPT will leverage its experience from the LEAP program in surface vessel detection to demonstrate an enhanced tracking technology covering a wider variety of vessels. This technology will feature an acoustic sensor system in addition to the existing HF RADAR. This will allow the PowerBuoy to collect data for ocean observing applications at the same time as it performs its enhanced surveillance duties, demonstrating the dual use of the PowerBuoy technology.

“Building on our success in 2011 with the LEAP deployment, we are pleased to be implementing this advanced maritime security payload on our Autonomous PowerBuoy” said Charles F. Dunleavy, Chief Executive Officer of OPT. “The CRADA and the grant from the MTDC will assist us in the expansion of the Autonomous PowerBuoy capability for vessel detection operations, which is one of the significant potential markets for this product. We look forward to deploying the upgraded device.”

Autonomous PowerBuoys form an important part of OPT’s commercial product offering, and have been designed to generate power for off-grid applications such as offshore oil & gas installations, fish-farming as well as security and maritime monitoring. In February 2012, OPT reported results of the LEAP program under which its device supplied continuous power in excess of 400W throughout the entire deployment and produced peak sustained electrical power of 1,500W, easily exceeding the critical design goals.

About Ocean Power Technologies

Ocean Power Technologies, Inc. (Nasdaq: OPTT) is a pioneer in wave-energy technology that harnesses ocean wave resources to generate reliable and clean and environmentally-beneficial electricity. OPT has a strong track record in the advancement of wave energy and participates in an estimated $150 billion annual power generation equipment market. OPT’s proprietary PowerBuoy® system is based on modular, ocean-going buoys that capture and convert predictable wave energy into clean electricity. The Company is widely recognized as a leading developer of on-grid and autonomous wave-energy generation systems, benefiting from 15 years of in-ocean experience. OPT is headquartered in Pennington, New Jersey, USA with an office in Warwick, UK, and operations in Melbourne and Perth, Australia. More information can be found at www.oceanpowertechnologies.com.

Forward-Looking Statements

This release may contain “forward-looking statements” that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the Company’s current expectations about its future plans and performance, including statements concerning the impact of marketing strategies, new product introductions and innovation, deliveries of product, sales, earnings and margins. These forward-looking statements rely on a number of assumptions and estimates which could be inaccurate and which are subject to risks and uncertainties. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company’s most recent Forms 10-Q and 10-K and subsequent filings with the SEC for a further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.

**********

Peregrine (PPHM) to Report Q1 Data Early, Phase II Bavituximab Second-Line Lung Cancer Trial

Peregrine to Report First Quarter Fiscal Year 2013 Financial Results Before Market on September 10, 2012

TUSTIN, CA — (Marketwire) — 09/04/12 — Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced that it will report financial results for the first quarter of the fiscal year 2013 on September 10, 2012 before market and will host a conference call and webcast at 8:00 AM PDT (11:00 AM EDT). Peregrine’s senior management will discuss financial results for the first quarter of fiscal year ended July 30, 2012 and will review progress of its clinical development programs, including an overview of the bavituximab data that will be presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology on September 7, 2012.

To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm.

To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call. A replay of the call will be available starting approximately two hours after the conclusion of the call through September 24, 2012 by calling (855) 859-2056, or (404) 537-3406 and using passcode 27367274.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
info@peregrineinc.com

Data From Peregrine’s Phase II Bavituximab Second-Line Lung Cancer Trial to Be Highlighted in Late-Breaking Oral Presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology

TUSTIN, CA — (Marketwire) — 09/04/12 — Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced it will be presenting data from its double-blind, placebo controlled, Phase II bavituximab trial in second-line non-small cell lung cancer at an upcoming plenary presentation at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology to be held at the Chicago Marriott Downtown Magnificent Mile in Chicago, Illinois from September 6-8, 2012. The late-breaking oral presentation will be held on September 7, 2012 at 1:40 PM CDT.

Oral Presentation Details:

Late-Breaking Plenary Presentation LBPL2

Title: Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Bavituximab Plus Docetaxel in Patients with Previously Treated Locally Advanced or Metastatic Non-Squamous Non-Small-Cell Lung Cancer (Top-line Results)

Speaker: David Gerber, M.D., University of Texas Southwestern Medical Center

Time: Friday, Sep 07, 2012, 1:40 PM – 1:50 PM CT

Authors: D. E. Gerber(1), M. Joppert(2), D. R. Spigel(3), D. P. Singh(4), D. Giorgadze(5), M. Shtivelband(6), O. V. Ponomarova(7), J. Shan(8), C. P. Belani(9)

1) Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX.; 2) Florida Cancer Specialists, Ft. Meyers, FL.; 3) Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN.; 4) Department of Radiotherapy & Clinical Oncology, S.M.S. Medical College & Attached Hospitals, Jaipur, India.; 5) Chemotherapy and Immunotherapy Clinic, Tbilisi, Georgia.; 6) Ironwood Cancer and Research Centers, Chandler, AZ.; 7) RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, Kiev, Ukraine.; 8) Peregrine Pharmaceuticals, Inc., Tustin, CA.; 9) Penn State Hershey Cancer Institute, Hershey, PA.

Audio Webcast
In conjunction with Dr. Gerber’s presentation in Chicago, Peregrine will post an audio webcast and slide deck to Peregrine’s website. The pre-recorded webcast will be hosted by Joseph Shan, vice president of clinical and regulatory affairs. Access to the audio and corresponding slides can be found on Peregrine’s website.

About Bavituximab
Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that represents a new approach to treating cancer. Bavituximab is the lead drug candidate from the company’s PS technology platform and is currently being tested in eight clinical trials including three randomized Phase II trials in front-line and second-line non-small cell lung cancer, front-line pancreatic cancer and five investigator-sponsored trials (ISTs) in additional oncology indications and treatment combinations.

PS is a highly immunosuppressive molecule usually located inside the membrane of healthy cells, but “flips” and becomes exposed on the outside of cells that line tumor blood vessels, creating a specific target for anti-cancer treatments. PS-targeting antibodies target and bind to PS and block this immunosuppressive signal, thereby enabling the immune system to recognize and fight the tumor.

About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in oncology with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

Add to Digg Bookmark with del.icio.us Add to Newsvine

Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals
(800) 987-8256
info@peregrineinc.com